{"protocolSection":{"identificationModule":{"nctId":"NCT02075840","orgStudyIdInfo":{"id":"BO28984"},"secondaryIdInfos":[{"id":"2013-004133-33","type":"EUDRACT_NUMBER"}],"organization":{"fullName":"Hoffmann-La Roche","class":"INDUSTRY"},"briefTitle":"A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants","officialTitle":"Randomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer","acronym":"ALEX"},"statusModule":{"statusVerifiedDate":"2025-07","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2014-08-19","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2017-02-09","type":"ACTUAL"},"completionDateStruct":{"date":"2025-04-28","type":"ACTUAL"},"studyFirstSubmitDate":"2014-02-27","studyFirstSubmitQcDate":"2014-02-27","studyFirstPostDateStruct":{"date":"2014-03-03","type":"ESTIMATED"},"resultsFirstSubmitDate":"2018-02-06","resultsFirstSubmitQcDate":"2018-02-16","resultsFirstPostDateStruct":{"date":"2018-03-15","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-07-15","lastUpdatePostDateStruct":{"date":"2025-07-25","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Hoffmann-La Roche","class":"INDUSTRY"}},"oversightModule":{"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This randomized, active controlled, multicenter phase III open-label study is designed to evaluate the efficacy and safety of alectinib compared with crizotinib treatment in participants with treatment-naive anaplastic lymphoma kinase-positive (ALK-positive) advanced non-small cell lung cancer (NSCLC). Participants will be randomized in a 1:1 ratio to receive either alectinib, 600 milligrams (mg) orally twice daily (BID), or crizotinib, 250 mg orally BID. Participants will receive treatment until disease progression, unacceptable toxicity, withdrawal of consent, or death. The study is expected to last approximately 144 months."},"conditionsModule":{"conditions":["Non-Small Cell Lung Cancer"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":303,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Alectinib","type":"EXPERIMENTAL","description":"Participants will receive alectinib from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death.","interventionNames":["Drug: Alectinib"]},{"label":"Crizotinib","type":"ACTIVE_COMPARATOR","description":"Participants will receive crizotinib from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death.","interventionNames":["Drug: Crizotinib"]}],"interventions":[{"type":"DRUG","name":"Alectinib","description":"Participants will receive alectinib 600 mg orally (four 150 mg capsules) BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death.","armGroupLabels":["Alectinib"],"otherNames":["RO5424802"]},{"type":"DRUG","name":"Crizotinib","description":"Participants will receive crizotinib 250 mg capsules orally BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death.","armGroupLabels":["Crizotinib"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Progression-Free Survival (PFS) by Investigator Assessment","description":"PFS was assessed as time to disease progression or death whichever occurred first by investigator assessment using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v1.1) Criteria. As per RECIST v1.1, disease progression is a 20% increase in the sum of the diameters of target lesions, an increase in size of measurable lesions by at least 5 millimeter (mm) and the appearance of new lesions.","timeFrame":"Randomization to first documented disease progression or death, whichever occurs first (assessed every 8 weeks up to 33 months)"},{"measure":"Percentage of Participants With PFS Event by Investigator Assessment","description":"PFS was assessed percentage of participants with disease progression or death whichever occurred first by investigator assessment using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v1.1) Criteria. As per RECIST v1.1, disease progression is a 20% increase in the sum of the diameters of target lesions, an increase in size of measurable lesions by at least 5 millimeter (mm) and the appearance of new lesions.","timeFrame":"Randomization to first documented disease progression or death, whichever occurs first (assessed every 8 weeks up to 33 months)"}],"secondaryOutcomes":[{"measure":"PFS Independent Review Committee (IRC)-Assessed","description":"PFS was assessed as time to disease progression or death whichever occurred first by IRC assessment using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v1.1) Criteria. As per RECIST v1.1, disease progression is a 20% increase in the sum of the diameters of target lesions, an increase in size of measurable lesions by at least 5 mm and the appearance of new lesions.","timeFrame":"Randomization to first documented disease progression or death, whichever occurs first (assessed every 8 weeks up to 33 months)"},{"measure":"Percentage of Participants With PFS Event by IRC","description":"PFS was assessed as percentage of participants with disease progression or death whichever occurred first by IRC assessment using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v1.1) Criteria. As per RECIST v1.1, disease progression is a 20% increase in the sum of the diameters of target lesions, an increase in size of measurable lesions by at least 5 mm and the appearance of new lesions.","timeFrame":"Randomization to first documented disease progression or death, whichever occurs first (assessed every 8 weeks up to 33 months)"},{"measure":"Percentage of Participants With Central Nervous System (CNS) Progression as Determined by IRC Using RECIST V1.1 Criteria","description":"CNS progression was assessed as percentage of participants with an event defined as time from randomization until first radiographic evidence of CNS progression by IRC. The risk for a CNS progression without a prior non-CNS progression with alectinib compared with crizotinib.","timeFrame":"Randomization to CNS PD as first occurrence of disease progression (assessed every 8 weeks up to 33 months)"},{"measure":"Percentage of Participants With Central Nervous System (CNS) Progression as Determined by IRC Using Revised Assessment in Neuro Oncology (RANO) Criteria","description":"CNS progression was assessed as percentage of participants with event defined as time from randomization until first radiographic evidence of CNS progression by IRC. The risk for a CNS progression without a prior non-CNS progression with alectinib compared with crizotinib.","timeFrame":"Randomization to the first occurrence of disease progression in the CNS (assessed every 8 weeks up to 33 months)"},{"measure":"Percentage of Participants With Objective Response Rate (ORR) of Complete Response (CR) or Partial Response (PR) as Determined by The Investigators According to RECIST V1.1 Criteria","description":"ORR was defined as the percentage of participants who attained CR or PR. As per RECIST v1.1, CR: Disappearance of all target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\< 10 mm, PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters.","timeFrame":"Randomization to first documented disease progression or death, whichever occurs first (assessed every 8 weeks up to 33 months)"},{"measure":"Duration of Response (DOR) According to RECIST V1.1 Criteria as Assessed by the Investigators","description":"DOR was defined as the time from when response (CR or PR) was first documented to first documented disease progression or death, whichever occurred first. DOR was evaluated for participants who had a best overall response (BOR) of CR or PR.","timeFrame":"First occurrence of objective response to first documented disease progression or death, whichever occurs first (assessed every 8 weeks up to 33 months)"},{"measure":"Overall Survival (OS)","description":"Overall survival (OS) was defined as the time from randomization to death from any cause.","timeFrame":"From randomization until death (up to 43 months)"},{"measure":"Percentage of Participants With OS Event","description":"Overall survival (OS) was defined as the time from randomization to death from any cause.","timeFrame":"From randomization until death (up to 43 months)"},{"measure":"Percentage of Participants With CNS ORR of CR or PR IRC-assessed According to RECIST v1.1 Criteria","description":"CNS ORR was defined as the percentage of participants who attained CR or PR and had measurable/non-measurable CNS lesions at baseline. As per RECIST v1.1, CR: Disappearance of all target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\< 10 mm, PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters.","timeFrame":"Randomization to first documented disease progression or death, whichever occurs first (assessed every 8 weeks up to 33 months)"},{"measure":"CNS DOR IRC-assessed According to RECIST v1.1 Criteria","description":"CNS DOR was defined as the time from when response (CR or PR) was first documented to first documented disease progression or death, whichever occurred first. DOR was evaluated for participants who had a best overall response (BOR) of CR or PR.","timeFrame":"First occurrence of CNS objective response to first documented disease progression or death, whichever occurs first (assessed every 8 weeks up to 33 months)"},{"measure":"Percentage of Participants With Adverse Events","description":"An adverse event (AE) is any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.","timeFrame":"Baseline up to 28 months in the crizotinib arm and up to 30 months in the alectinib arm"},{"measure":"Area Under The Concentration-Time Curve (AUC) of Alectinib","timeFrame":"Pre-dose (within 2 hours before alectinib) (baseline), 1, 2, 4, 6, and 8 hours post-dose at Visit 0 (first dosing day) and Week 4; Pre-dose (within 2 hours) at Week 8, then every 8 weeks until disease progression or death/withdrawal (up to 33 months)"},{"measure":"Maximum Concentration (Cmax) of Alectinib","timeFrame":"Pre-dose (within 2 hours before alectinib), 1, 2, 4, 6, and 8 hours post-dose at baseline and Week 4; Pre-dose (within 2 hours before alectinib) at Week 8, then every 8 weeks until disease progression or death/withdrawal from study (up to 33 months)"},{"measure":"Time to Reach Cmax (Tmax) of Alectinib","timeFrame":"Pre-dose (within 2 hours before alectinib), 1, 2, 4, 6, and 8 hours post-dose at baseline and Week 4; Pre-dose (within 2 hours before alectinib) at Week 8, then every 8 weeks until disease progression or death/withdrawal from study (up to 33 months)"},{"measure":"AUC of Alectinib Metabolite","timeFrame":"Pre-dose (within 2 hours before alectinib) (baseline), 1, 2, 4, 6, and 8 hours post-dose at Visit 0 (first dosing day) and Week 4; Pre-dose (within 2 hours) at Week 8, then every 8 weeks until disease progression or death/withdrawal (up to 33 months)"},{"measure":"Cmax of Alectinib Metabolite","timeFrame":"Pre-dose (within 2 hours before alectinib), 1, 2, 4, 6, and 8 hours post-dose at baseline and Week 4; Pre-dose (within 2 hours before alectinib) at Week 8, then every 8 weeks until disease progression or death/withdrawal from study (up to 33 months)"},{"measure":"Tmax of Alectinib Metabolite","timeFrame":"Pre-dose (within 2 hours before alectinib), 1, 2, 4, 6, and 8 hours post-dose at baseline and Week 4; Pre-dose (within 2 hours before alectinib) at Week 8, then every 8 weeks until disease progression or death/withdrawal from study (up to 33 months)"},{"measure":"Time to Deterioration by European Organization for The Research And Treatment of Cancer (EORTC) Quality Of Life Questionnaire Core 30 (C30)","description":"The EORTC QLQ-30 module generated one multiple-item scale score assessing dyspnea and a series of single item scores assessing chest pain, arm/shoulder pain, pain in other parts, coughing, sore mouth, dysphagia, peripheral neuropathy, alopecia, and hemoptysis. All the scales and single-item scores were linearly transformed so that each score ranged from 0 to 100. A higher score on the global health and functioning subscales is indicative of better functioning. Confirmed clinically meaningful deterioration in global health status or function is defined as a \\>or=10-point decrease from baseline in a symptom score that must be held for at least two consecutive assessments or an initial \\>or=10-point decrease from baseline followed by death within 5 weeks from the last assessment.","timeFrame":"Baseline, every 4 weeks until disease progression (up to 33 months)"},{"measure":"Percentage of Participants With Deterioration by EORTC Quality Of Life Questionnaire Core 30 (C30)","description":"The EORTC QLQ-30 module generated one multiple-item scale score assessing dyspnea and a series of single item scores assessing chest pain, arm/shoulder pain, pain in other parts, coughing, sore mouth, dysphagia, peripheral neuropathy, alopecia, and hemoptysis. All the scales and single-item scores were linearly transformed so that each score ranged from 0 to 100. A higher score on the global health and functioning subscales is indicative of better functioning. Confirmed clinically meaningful deterioration in global health status or function is defined as a \\>or=10-point decrease from baseline in a symptom score that must be held for at least two consecutive assessments or an initial \\>or=10-point decrease from baseline followed by death within 5 weeks from the last assessment.","timeFrame":"Baseline, every 4 weeks until disease progression (up to 33 months)"},{"measure":"Time to Deterioration by EORTC Quality of Life Questionnaire Lung Cancer Module 13 (LC13)","description":"The EORTC QLQ-LC13 module generated one multiple-item scale score assessing dyspnea and a series of single item scores assessing chest pain, arm/shoulder pain, pain in other parts, coughing, sore mouth, dysphagia, peripheral neuropathy, alopecia, and hemoptysis. All the scales and single-item scores were linearly transformed so that each score ranged from 0 to 100. A higher score on the global health and functioning subscales is indicative of better functioning. Confirmed clinically meaningful deterioration in lung cancer symptoms is defined as a \\>or=10-point increase from baseline in a symptom score that must be held for at least two consecutive assessments or an initial \\>or=10-point increase above baseline followed by death within 5 weeks from the last assessment.","timeFrame":"Baseline, every 4 weeks until disease progression (up to 33 months)"},{"measure":"Percentage of Participants With Deterioration by EORTC Quality of Life Questionnaire Lung Cancer Module 13 (LC13)","description":"The EORTC QLQ-LC13 module generated one multiple-item scale score assessing dyspnea and a series of single item scores assessing chest pain, arm/shoulder pain, pain in other parts, coughing, sore mouth, dysphagia, peripheral neuropathy, alopecia, and hemoptysis. All the scales and single-item scores were linearly transformed so that each score ranged from 0 to 100. A higher score on the global health and functioning subscales is indicative of better functioning. Confirmed clinically meaningful deterioration in lung cancer symptoms is defined as a \\>or=10-point increase from baseline in a symptom score that must be held for at least two consecutive assessments or an initial \\>or=10-point increase above baseline followed by death within 5 weeks from the last assessment.","timeFrame":"Baseline, every 4 weeks until disease progression (up to 33 months)"},{"measure":"Health-Related Quality of Life (HRQoL) by EORTC Quality of Life Questionnaire C30 Score","description":"The EORTC QLQ-C30 questionnaire consisted of 30 questions generating five functional scores (physical, role, cognitive, emotional, and social); a global health status/global quality of life scale score; three symptom scale scores (fatigue, pain, and nausea and vomiting); and six stand alone one-item scores that capture additional symptoms (dyspnea, appetite loss, sleep disturbance, constipation, and diarrhea) and perceived financial burden. All the scales and single-item scores were linearly transformed so that each score ranged from 0 to 100. A higher score on the global health and functioning subscales is indicative of better functioning.","timeFrame":"Baseline, every 4 weeks until disease progression (up to 33 months)"},{"measure":"HRQoL by EORTC Quality of Life Questionnaire LC13 Score Coughing","description":"The EORTC QLQ-LC13 module generated one multiple-item scale score assessing dyspnea and a series of single item scores assessing chest pain, arm/shoulder pain, pain in other parts, coughing, sore mouth, dysphagia, peripheral neuropathy, alopecia, and hemoptysis. All the scales and single-item scores were linearly transformed so that each score ranged from 0 to 100. A higher score on the global health and functioning subscales is indicative of better functioning.","timeFrame":"Baseline, every 4 weeks until disease progression (up to 33 months)"},{"measure":"HRQoL by EORTC Quality of Life Questionnaire LC13 Score Dyspnoea","description":"The EORTC QLQ-LC13 module generated one multiple-item scale score assessing dyspnea and a series of single item scores assessing chest pain, arm/shoulder pain, pain in other parts, coughing, sore mouth, dysphagia, peripheral neuropathy, alopecia, and hemoptysis. All the scales and single-item scores were linearly transformed so that each score ranged from 0 to 100. A higher score on the global health and functioning subscales is indicative of better functioning.","timeFrame":"Baseline, every 4 weeks until disease progression (up to 33 months)"},{"measure":"HRQoL by EORTC Quality of Life Questionnaire LC13 Score Pain in Chest","description":"The EORTC QLQ-LC13 module generated one multiple-item scale score assessing dyspnea and a series of single item scores assessing chest pain, arm/shoulder pain, pain in other parts, coughing, sore mouth, dysphagia, peripheral neuropathy, alopecia, and hemoptysis. All the scales and single-item scores were linearly transformed so that each score ranged from 0 to 100. A higher score on the global health and functioning subscales is indicative of better functioning.","timeFrame":"Baseline, every 4 weeks until disease progression (up to 33 months)"},{"measure":"HRQoL by EORTC Quality of Life Questionnaire LC13 Score Pain in Arm and Shoulder","description":"The EORTC QLQ-LC13 module generated one multiple-item scale score assessing dyspnea and a series of single item scores assessing chest pain, arm/shoulder pain, pain in other parts, coughing, sore mouth, dysphagia, peripheral neuropathy, alopecia, and hemoptysis. All the scales and single-item scores were linearly transformed so that each score ranged from 0 to 100. A higher score on the global health and functioning subscales is indicative of better functioning.","timeFrame":"Baseline, every 4 weeks until disease progression (up to 33 months)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Histologically or cytologically confirmed diagnosis of advanced or recurrent (Stage IIIB not amenable for multimodality treatment) or metastatic (Stage IV) NSCLC that is ALK-positive as assessed by the Ventana immunohistochemistry (IHC) test\n* Life expectancy of at least 12 weeks\n* Eastern cooperative oncology group performance status (ECOG PS) of 0-2\n* Participants with no prior systemic treatment for advanced or recurrent (Stage IIIB not amenable for multimodality treatment) or metastatic (Stage IV) NSCLC\n* Adequate renal, and hematologic function\n* Participants must have recovered from effects of any major surgery or significant traumatic injury at least 28 days before the first dose of study treatment\n* Measurable disease by response evaluation criteria in solid tumors (RECIST) version 1.1 (v1.1) prior to the administration of study treatment\n* Prior brain or leptomeningeal metastases allowed if asymptomatic (e.g., diagnosed incidentally at study baseline)\n* Negative pregnancy test for all females of child bearing potential\n* Use of highly effective contraception as defined by the study protocol\n\nExclusion Criteria:\n\n* Participants with a previous malignancy within the past 3 years\n* Any gastrointestinal (GI) disorder or liver disease\n* National cancer institute common terminology criteria for adverse events (NCI CTCAE) (version 4.0) Grade 3 or higher toxicities due to any prior therapy (e.g., radiotherapy) (excluding alopecia)\n* History of organ transplant\n* Co-administration of anti-cancer therapies other than those administered in this study\n* Participants with baseline QTc greater than (\\>) 470 milliseconds or symptomatic bradycardia\n* Recipient of strong/potent cytochrome P4503A inhibitors or inducers within 14 days prior to the first dose until the end of study treatment\n* Recipient of any drug with potential QT interval prolonging effects within 14 days prior to the first dose for all participants and while on treatment through the end of the study for crizotinib-treated participants only\n* History of hypersensitivity to any of the additives in the alectinib and crizotinib drug formulation\n* Pregnancy or lactation\n* Any clinically significant disease or condition (or history of) that could interfere with, or for which the treatment might interfere with, the conduct of the study or the absorption of oral medications or that would, in the opinion of the principal investigator, pose an unacceptable risk to the participant in this study\n* Any psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol requirements and/or follow-up procedures; those conditions should be discussed with the participant before trial entry","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Clinical Trials","affiliation":"Hoffmann-La Roche","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"North Valley Hem Onc Med Grp","city":"Northridge","state":"California","zip":"91325","country":"United States","geoPoint":{"lat":34.22834,"lon":-118.53675}},{"facility":"TMPN/ Cancer Care Associates","city":"Redondo Beach","state":"California","zip":"90277","country":"United States","geoPoint":{"lat":33.84918,"lon":-118.38841}},{"facility":"University of Colorado Cancer Center","city":"Aurora","state":"Colorado","zip":"80045","country":"United States","geoPoint":{"lat":39.72943,"lon":-104.83192}},{"facility":"University of Miami-Deerfield Beach","city":"Deerfield Beach","state":"Florida","zip":"33442","country":"United States","geoPoint":{"lat":26.31841,"lon":-80.09977}},{"facility":"Massachusetts General Hospital Cancer Center","city":"Boston","state":"Massachusetts","zip":"02114","country":"United States","geoPoint":{"lat":42.35843,"lon":-71.05977}},{"facility":"Beth Israel Deaconess Med Ctr","city":"Boston","state":"Massachusetts","zip":"02215","country":"United States","geoPoint":{"lat":42.35843,"lon":-71.05977}},{"facility":"Dana Farber Can Ins","city":"Boston","state":"Massachusetts","zip":"02215","country":"United States","geoPoint":{"lat":42.35843,"lon":-71.05977}},{"facility":"Karmanos Cancer Institute","city":"Detroit","state":"Michigan","zip":"48201","country":"United States","geoPoint":{"lat":42.33143,"lon":-83.04575}},{"facility":"Washington Uni School of Medicine","city":"St Louis","state":"Missouri","zip":"63110","country":"United States","geoPoint":{"lat":38.62727,"lon":-90.19789}},{"facility":"SCRI Oncology Partners","city":"Nashville","state":"Tennessee","zip":"37203","country":"United States","geoPoint":{"lat":36.16589,"lon":-86.78444}},{"facility":"University of Texas M.D. Anderson Cancer Center","city":"Houston","state":"Texas","zip":"77030","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"Kinghorn Cancer Centre","city":"Darlinghurst","state":"New South Wales","zip":"2010","country":"Australia","geoPoint":{"lat":-33.87939,"lon":151.21925}},{"facility":"Royal North Shore Hospital","city":"St Leonards","state":"New South Wales","zip":"2065","country":"Australia","geoPoint":{"lat":-33.82344,"lon":151.19836}},{"facility":"Calvary Mater Newcastle","city":"Waratah","state":"New South Wales","zip":"2298","country":"Australia","geoPoint":{"lat":-32.90667,"lon":151.72647}},{"facility":"Queen Elizabeth Hospital","city":"Adelaide","state":"South Australia","zip":"5011","country":"Australia","geoPoint":{"lat":-34.92866,"lon":138.59863}},{"facility":"Monash Health Translational Precinct","city":"Victoria","state":"Victoria","zip":"3168","country":"Australia"},{"facility":"University Clinical Center Sarajevo","city":"Sarajevo","zip":"71000","country":"Bosnia and Herzegovina","geoPoint":{"lat":43.84864,"lon":18.35644}},{"facility":"Instituto do Cancer do Estado de Sao Paulo - ICESP","city":"São Paulo","state":"São Paulo","zip":"01246-000","country":"Brazil","geoPoint":{"lat":-23.5475,"lon":-46.63611}},{"facility":"Cross Cancer Institute","city":"Edmonton","state":"Alberta","zip":"T6G 1Z2","country":"Canada","geoPoint":{"lat":53.55014,"lon":-113.46871}},{"facility":"Sunnybrook Odette Cancer Centre","city":"Toronto","state":"Ontario","zip":"M4N 3M5","country":"Canada","geoPoint":{"lat":43.70643,"lon":-79.39864}},{"facility":"Mount Sinai Hospital","city":"Toronto","state":"Ontario","zip":"M5G 1X5","country":"Canada","geoPoint":{"lat":43.70643,"lon":-79.39864}},{"facility":"Saskatoon Cancer Centre","city":"Saskatoon","state":"Saskatchewan","zip":"S7N 4H4","country":"Canada","geoPoint":{"lat":52.13238,"lon":-106.66892}},{"facility":"Centro Internacional de Estudios Clínicos (CIEC)","city":"Santiago","zip":"8420383","country":"Chile","geoPoint":{"lat":-33.45694,"lon":-70.64827}},{"facility":"Sun Yet-sen University Cancer Center","city":"Guangzhou","zip":"510060","country":"China","geoPoint":{"lat":23.11667,"lon":113.25}},{"facility":"Shanghai Pulmonary Hospital","city":"Shanghai","zip":"200433","country":"China","geoPoint":{"lat":31.22222,"lon":121.45806}},{"facility":"Clinica CIMCA","city":"San José","zip":"DUMMY_VALUE","country":"Costa Rica","geoPoint":{"lat":9.93388,"lon":-84.08489}},{"facility":"Kasr Eieny Uni Hospital","city":"Cairo","zip":"11555","country":"Egypt","geoPoint":{"lat":30.06263,"lon":31.24967}},{"facility":"Chu Grenoble - Hopital Albert Michallon","city":"Grenoble","zip":"38043","country":"France","geoPoint":{"lat":45.17869,"lon":5.71479}},{"facility":"CHRU de Lille","city":"Lille","zip":"59037","country":"France","geoPoint":{"lat":50.63391,"lon":3.05512}},{"facility":"Centre Leon Berard","city":"Lyon","zip":"69373","country":"France","geoPoint":{"lat":45.74906,"lon":4.84789}},{"facility":"Hopital Haut Leveque","city":"Pessac","zip":"33604","country":"France","geoPoint":{"lat":44.80565,"lon":-0.6324}},{"facility":"Grupo Angeles","city":"Guatemala City","zip":"01015","country":"Guatemala","geoPoint":{"lat":14.64072,"lon":-90.51327}},{"facility":"Tuen Mun Hospital","city":"Hong Kong","zip":"852","country":"Hong Kong","geoPoint":{"lat":22.27832,"lon":114.17469}},{"facility":"Pamela Youde Nethersole Eastern Hospital","city":"Hong Kong","zip":"DUMMY_VALUE","country":"Hong Kong","geoPoint":{"lat":22.27832,"lon":114.17469}},{"facility":"Princess Margaret Hospital","city":"Hong Kong","zip":"DUMMY_VALUE","country":"Hong Kong","geoPoint":{"lat":22.27832,"lon":114.17469}},{"facility":"Queen Mary Hospital","city":"Hong Kong","zip":"DUMMY_VALUE","country":"Hong Kong","geoPoint":{"lat":22.27832,"lon":114.17469}},{"facility":"Prince of Wales Hosp","city":"Hong Kong","country":"Hong Kong","geoPoint":{"lat":22.27832,"lon":114.17469}},{"facility":"Rambam Medical Center","city":"Haifa","zip":"4959381","country":"Israel","geoPoint":{"lat":32.81303,"lon":34.99928}},{"facility":"Meir Medical Center","city":"Kfar Saba","zip":"44281","country":"Israel","geoPoint":{"lat":32.175,"lon":34.90694}},{"facility":"Irccs Ist. Tumori Giovanni Paolo Ii","city":"Bari","state":"Apulia","zip":"70124","country":"Italy","geoPoint":{"lat":41.12066,"lon":16.86982}},{"facility":"A.O. Universitaria Di Parma","city":"Parma","state":"Emilia-Romagna","zip":"43100","country":"Italy","geoPoint":{"lat":44.79935,"lon":10.32618}},{"facility":"Ospedale Provinciale Santa Maria Delle Croci","city":"Ravenna","state":"Emilia-Romagna","zip":"48100","country":"Italy","geoPoint":{"lat":44.41344,"lon":12.20121}},{"facility":"Policlinico Umberto i di Roma","city":"Rome","state":"Lazio","zip":"00161","country":"Italy","geoPoint":{"lat":41.89193,"lon":12.51133}},{"facility":"Irccs Istituto Nazionale Dei Tumori (Int)","city":"Milan","state":"Lombardy","zip":"20133","country":"Italy","geoPoint":{"lat":45.46427,"lon":9.18951}},{"facility":"Irccs Istituto Europeo Di Oncologia (IEO)","city":"Milan","state":"Lombardy","zip":"20141","country":"Italy","geoPoint":{"lat":45.46427,"lon":9.18951}},{"facility":"Azienda Ospedaliero-Universitaria San Luigi Gonzaga","city":"Orbassano","state":"Piedmont","zip":"10043","country":"Italy","geoPoint":{"lat":45.00547,"lon":7.53813}},{"facility":"Az Ospedaliera Nuovo Garibaldi Quartiere Nesima","city":"Catania","state":"Sicily","zip":"95122","country":"Italy","geoPoint":{"lat":37.49223,"lon":15.07041}},{"facility":"Azienda Ospedaliera Di Perugia Ospedale s. Maria Della Misericordia","city":"Perugia","state":"Umbria","zip":"06156","country":"Italy","geoPoint":{"lat":43.1122,"lon":12.38878}},{"facility":"Instituto Nacional De Enfermedades Respiratorias","city":"Mexico City","state":"Mexico CITY (federal District)","zip":"14080","country":"Mexico","geoPoint":{"lat":19.42847,"lon":-99.12766}},{"facility":"Uni of Auckland","city":"Auckland","zip":"DUMMY_VALUE","country":"New Zealand","geoPoint":{"lat":-36.84853,"lon":174.76349}},{"facility":"Uniwersyteckie Centrum Kliniczne","city":"Gda?sk","zip":"80-214","country":"Poland"},{"facility":"Ms Clinsearch Specjalistyczny Niepubliczny Zaklad Opieki Zdrowotnej","city":"Lublin","zip":"20-064","country":"Poland","geoPoint":{"lat":51.25058,"lon":22.57009}},{"facility":"Warminsko-Mazurskie Centrum Chorób P?uc w Olsztynie","city":"Olsztyn","zip":"10-357","country":"Poland","geoPoint":{"lat":53.78376,"lon":20.49272}},{"facility":"Centrum Onkologii - Inst.Im. Marii Sklodowskiej-Curie","city":"Warsaw","zip":"02-781","country":"Poland","geoPoint":{"lat":52.22977,"lon":21.01178}},{"facility":"CHUC - Unidade de Pneumologia Oncológica","city":"Coimbra","zip":"3000-075","country":"Portugal","geoPoint":{"lat":40.20686,"lon":-8.41996}},{"facility":"IPO de Lisboa","city":"Lisbon","zip":"1099-023","country":"Portugal","geoPoint":{"lat":38.72509,"lon":-9.1498}},{"facility":"IPO do Porto","city":"Porto","zip":"4200-072","country":"Portugal","geoPoint":{"lat":41.1485,"lon":-8.61097}},{"facility":"Moscow City Oncology Hospital #62","city":"Moscovskaya Oblast","state":"Moscow Oblast","zip":"143423","country":"Russia"},{"facility":"SPb City Clin Onc Dsp","city":"Saint Petersburg","state":"Sankt-Peterburg","zip":"197022","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"Scientific Research Oncology Institute named after N.N. Petrov","city":"Saint Petersburg","state":"Sankt-Peterburg","zip":"197758","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"N.N.Burdenko Main Military Clinical Hospital","city":"Moscow","zip":"105229","country":"Russia","geoPoint":{"lat":55.75204,"lon":37.61781}},{"facility":"Clinical Center of Serbia","city":"Belgrade","zip":"11000","country":"Serbia","geoPoint":{"lat":44.80401,"lon":20.46513}},{"facility":"Institute for pulmonary diseases of Vojvodina","city":"Kamenitz","zip":"21204","country":"Serbia","geoPoint":{"lat":45.22334,"lon":19.84263}},{"facility":"National University Hospital","city":"Singapore","zip":"119228","country":"Singapore","geoPoint":{"lat":1.28967,"lon":103.85007}},{"facility":"National Cancer Centre","city":"Singapore","zip":"169610","country":"Singapore","geoPoint":{"lat":1.28967,"lon":103.85007}},{"facility":"National Cancer Center","city":"Gyeonggi-do","zip":"10408","country":"South Korea","geoPoint":{"lat":37.58944,"lon":126.76917}},{"facility":"Seoul National University Bundang Hospital","city":"Gyeonggi-do","zip":"13620","country":"South Korea","geoPoint":{"lat":37.58944,"lon":126.76917}},{"facility":"Seoul National University Hospital","city":"Seoul","zip":"03080","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Severance Hospital, Yonsei University Health System","city":"Seoul","zip":"03722","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Asan Medical Center","city":"Seoul","zip":"05505","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Samsung Medical Center","city":"Seoul","zip":"06351","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Hospital General Univ. de Alicante","city":"Alicante","zip":"3010","country":"Spain","geoPoint":{"lat":38.34517,"lon":-0.48149}},{"facility":"Vall d'Hebron Institute of Oncology (VHIO), Barcelona","city":"Barcelona","zip":"08035","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Hospital Universitari Germans Trias i Pujol","city":"Barcelona","zip":"08916","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Hospital Universitario Puerta de Hierro","city":"Madrid","zip":"28222","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Hospital Universitario Virgen del Rocio","city":"Seville","zip":"41013","country":"Spain","geoPoint":{"lat":37.38283,"lon":-5.97317}},{"facility":"Universitaetsspital Basel","city":"Basel","zip":"4031","country":"Switzerland","geoPoint":{"lat":47.55839,"lon":7.57327}},{"facility":"Inselspital Bern","city":"Bern","zip":"3010","country":"Switzerland","geoPoint":{"lat":46.94809,"lon":7.44744}},{"facility":"CHUV","city":"Lausanne","zip":"1011","country":"Switzerland","geoPoint":{"lat":46.516,"lon":6.63282}},{"facility":"UniversitätsSpital Zürich","city":"Zurich","zip":"8091","country":"Switzerland","geoPoint":{"lat":47.36667,"lon":8.55}},{"facility":"Taichung Veterans General Hospital","city":"Taichung","zip":"40705","country":"Taiwan","geoPoint":{"lat":24.1469,"lon":120.6839}},{"facility":"National Cheng Kung Univ Hosp","city":"Tainan","zip":"00704","country":"Taiwan","geoPoint":{"lat":22.99083,"lon":120.21333}},{"facility":"National Taiwan University Hospital","city":"Taipei","zip":"00100","country":"Taiwan","geoPoint":{"lat":25.05306,"lon":121.52639}},{"facility":"Taipei Veterans General Hospital","city":"Taipei","zip":"00112","country":"Taiwan","geoPoint":{"lat":25.05306,"lon":121.52639}},{"facility":"National Cancer Inst.","city":"Bangkok","zip":"10400","country":"Thailand","geoPoint":{"lat":13.75398,"lon":100.50144}},{"facility":"Chiang Rai Prachanukroh Hospital","city":"Chiang Rai","zip":"57000","country":"Thailand","geoPoint":{"lat":19.90858,"lon":99.8325}},{"facility":"Khonkaen Hospital","city":"Khonkaen","zip":"40000","country":"Thailand"},{"facility":"King Chulalongkorn Memorial Hospital","city":"Patumwan","zip":"10330","country":"Thailand"},{"facility":"Songklanagarind Hospital","city":"Songkhla","zip":"90110","country":"Thailand","geoPoint":{"lat":7.19882,"lon":100.5951}},{"facility":"Baskent University Adana Dr. Turgut Noyan Practice and Research Hospital","city":"Adana","zip":"01250","country":"Turkey (Türkiye)","geoPoint":{"lat":36.98615,"lon":35.32531}},{"facility":"Ankara University Medical Faculty","city":"Ankara","zip":"06100","country":"Turkey (Türkiye)","geoPoint":{"lat":39.91987,"lon":32.85427}},{"facility":"Trakya University Medical Faculty Research And Practice Hospital Medical Oncology Department","city":"Edirne","zip":"22770","country":"Turkey (Türkiye)","geoPoint":{"lat":41.67719,"lon":26.55597}},{"facility":"Inonu University Medical Faculty Turgut Ozal Medical Center Medical Oncology Department","city":"Malatya","zip":"44280","country":"Turkey (Türkiye)","geoPoint":{"lat":38.35018,"lon":38.31667}},{"facility":"Kyiv Regional Oncological Dispensary","city":"Kyiv","zip":"04107","country":"Ukraine","geoPoint":{"lat":50.45466,"lon":30.5238}},{"facility":"Lviv State Oncology Regional Treatment and Diagnostic Centre","city":"Lviv","zip":"79031","country":"Ukraine","geoPoint":{"lat":49.83826,"lon":24.02324}},{"facility":"Birmingham Heartlands Hospital","city":"Birmingham","zip":"B9 5SS","country":"United Kingdom","geoPoint":{"lat":52.48142,"lon":-1.89983}},{"facility":"University College London Hospital","city":"London","zip":"NW1 - 2PG","country":"United Kingdom","geoPoint":{"lat":51.50853,"lon":-0.12574}},{"facility":"Guys & St Thomas Hospital","city":"London","zip":"SE1 9RT","country":"United Kingdom","geoPoint":{"lat":51.50853,"lon":-0.12574}}]},"referencesModule":{"references":[{"pmid":"39661917","type":"DERIVED","citation":"Sikkema BJ, Baart SJ, Paats MS, Smit EF, Schols AMWJ, Mathijssen RHJ, van Rossum EFC, Dingemans AC. Body Weight Gain Associated With Alectinib in Patients With ALK+ Non-Small Cell Lung Cancer: Pooled Analysis of Individual Patient Data From Four Prospective Clinical Trials. J Clin Oncol. 2025 Feb 20;43(6):641-650. doi: 10.1200/JCO-24-01579. Epub 2024 Dec 11."},{"pmid":"35275991","type":"DERIVED","citation":"Dziadziuszko R, Peters S, Mok T, Camidge DR, Gadgeel SM, Ou SI, Konopa K, Noe J, Nowicka M, Bordogna W, Morcos PN, Smoljanovic V, Shaw AT. Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced ALK+ Non-small Cell Lung Cancer in the Global Phase III ALEX Trial. Clin Cancer Res. 2022 May 2;28(9):1800-1808. doi: 10.1158/1078-0432.CCR-21-2840."},{"pmid":"32418886","type":"DERIVED","citation":"Mok T, Camidge DR, Gadgeel SM, Rosell R, Dziadziuszko R, Kim DW, Perol M, Ou SI, Ahn JS, Shaw AT, Bordogna W, Smoljanovic V, Hilton M, Ruf T, Noe J, Peters S. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study. Ann Oncol. 2020 Aug;31(8):1056-1064. doi: 10.1016/j.annonc.2020.04.478. Epub 2020 May 11."},{"pmid":"30215676","type":"DERIVED","citation":"Gadgeel S, Peters S, Mok T, Shaw AT, Kim DW, Ou SI, Perol M, Wrona A, Novello S, Rosell R, Zeaiter A, Liu T, Nuesch E, Balas B, Camidge DR. Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study. Ann Oncol. 2018 Nov 1;29(11):2214-2222. doi: 10.1093/annonc/mdy405."},{"pmid":"29656744","type":"DERIVED","citation":"Burudpakdee C, Wong W, Seetasith A, Corvino FA, Yeh W, Gubens M. Economic impact of preventing brain metastases with alectinib in ALK-positive non-small cell lung cancer. Lung Cancer. 2018 May;119:103-111. doi: 10.1016/j.lungcan.2018.03.008. Epub 2018 Mar 9."},{"pmid":"28586279","type":"DERIVED","citation":"Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW, Ou SI, Perol M, Dziadziuszko R, Rosell R, Zeaiter A, Mitry E, Golding S, Balas B, Noe J, Morcos PN, Mok T; ALEX Trial Investigators. Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2017 Aug 31;377(9):829-838. doi: 10.1056/NEJMoa1704795. Epub 2017 Jun 6."},{"pmid":"28501139","type":"DERIVED","citation":"Gainor JF, Shaw AT. J-ALEX: alectinib versus crizotinib in ALK-positive lung cancer. Lancet. 2017 Jul 1;390(10089):3-4. doi: 10.1016/S0140-6736(17)31074-7. Epub 2017 May 10. No abstract available."}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"A total of 303 participants were randomized at the time of clinical cut-off (CCO) date on 9 February 2017 and included in the intent-to-treat (ITT) population; 152 participants in the alectinib arm and 151 participants in the crizotinib arm.","recruitmentDetails":"The study recruited treatment-naive participants with Anaplastic Lymphoma Kinase (ALK)-positive advanced Non-Small Cell Lung Cancer (NSCLC) in 29 countries from August 2014 to January 2016.","groups":[{"id":"FG000","title":"Alectinib","description":"Participants received alectinib at 600 mg orally BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death."},{"id":"FG001","title":"Crizotinib","description":"Participants received crizotinib at 250 mg orally BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"152"},{"groupId":"FG001","numSubjects":"151"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"152"},{"groupId":"FG001","numSubjects":"151"}]}],"dropWithdraws":[{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"13"},{"groupId":"FG001","numSubjects":"22"}]},{"type":"Reason not specified","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"2"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"35"},{"groupId":"FG001","numSubjects":"40"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"2"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"3"}]},{"type":"Ongoing at CCOD","reasons":[{"groupId":"FG000","numSubjects":"99"},{"groupId":"FG001","numSubjects":"82"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Analysis was performed on intent to treat (ITT) population which included all randomized participants in the study.","groups":[{"id":"BG000","title":"Alectinib","description":"Participants received alectinib at 600 mg orally BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death."},{"id":"BG001","title":"Crizotinib","description":"Participants received crizotinib at 250 mg orally BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"152"},{"groupId":"BG001","value":"151"},{"groupId":"BG002","value":"303"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"56.3","spread":"12.0"},{"groupId":"BG001","value":"53.8","spread":"13.5"},{"groupId":"BG002","value":"55.1","spread":"12.8"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"84"},{"groupId":"BG001","value":"87"},{"groupId":"BG002","value":"171"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"68"},{"groupId":"BG001","value":"64"},{"groupId":"BG002","value":"132"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"NUMBER","unitOfMeasure":"Participants","classes":[{"title":"Ethnicity - Hispanic or Latino","categories":[{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"16"}]}]},{"title":"Ethinicity - Not Hispanic or Latino","categories":[{"measurements":[{"groupId":"BG000","value":"138"},{"groupId":"BG001","value":"136"},{"groupId":"BG002","value":"274"}]}]},{"title":"Ethnicity - Not Stated","categories":[{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"13"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"NUMBER","unitOfMeasure":"Participants","classes":[{"title":"Race - American Indian or Alaska Native","categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"4"}]}]},{"title":"Race - Asian","categories":[{"measurements":[{"groupId":"BG000","value":"69"},{"groupId":"BG001","value":"69"},{"groupId":"BG002","value":"138"}]}]},{"title":"Race - Black or African American","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"4"}]}]},{"title":"Race - Native Hawaiian or other Pacific Islander","categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"}]}]},{"title":"Race - White","categories":[{"measurements":[{"groupId":"BG000","value":"76"},{"groupId":"BG001","value":"75"},{"groupId":"BG002","value":"151"}]}]},{"title":"Race - Unknown","categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"4"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Progression-Free Survival (PFS) by Investigator Assessment","description":"PFS was assessed as time to disease progression or death whichever occurred first by investigator assessment using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v1.1) Criteria. As per RECIST v1.1, disease progression is a 20% increase in the sum of the diameters of target lesions, an increase in size of measurable lesions by at least 5 millimeter (mm) and the appearance of new lesions.","populationDescription":"ITT population included all randomized participants in the study. Number of participants analyzed is the total participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Randomization to first documented disease progression or death, whichever occurs first (assessed every 8 weeks up to 33 months)","groups":[{"id":"OG000","title":"Alectinib","description":"Participants received alectinib at 600 mg orally BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death."},{"id":"OG001","title":"Crizotinib","description":"Participants received crizotinib at 250 mg orally BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"152"},{"groupId":"OG001","value":"151"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","lowerLimit":"17.7","upperLimit":"NA","comment":"The median PFS had not been reached in the alectinib arm at the time of data cutoff date (9 Feb 2017)."},{"groupId":"OG001","value":"11.1","lowerLimit":"9.1","upperLimit":"13.1"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Stratified hazard ratio and p-value are stratified for covariates Race (Asian vs Non-Asian) and CNS metastases at baseline by IRC.","nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","statisticalMethod":"Log Rank","paramType":"Hazard Ratio, stratified","paramValue":"0.47","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.34","ciUpperLimit":"0.65"}]},{"type":"PRIMARY","title":"Percentage of Participants With PFS Event by Investigator Assessment","description":"PFS was assessed percentage of participants with disease progression or death whichever occurred first by investigator assessment using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v1.1) Criteria. As per RECIST v1.1, disease progression is a 20% increase in the sum of the diameters of target lesions, an increase in size of measurable lesions by at least 5 millimeter (mm) and the appearance of new lesions.","populationDescription":"ITT population included all randomized participants in the study. Number of participants analyzed is the total participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of Participants","timeFrame":"Randomization to first documented disease progression or death, whichever occurs first (assessed every 8 weeks up to 33 months)","groups":[{"id":"OG000","title":"Alectinib","description":"Participants received alectinib at 600 mg orally BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death."},{"id":"OG001","title":"Crizotinib","description":"Participants received crizotinib at 250 mg orally BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"152"},{"groupId":"OG001","value":"151"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40.8"},{"groupId":"OG001","value":"67.5"}]}]}]},{"type":"SECONDARY","title":"PFS Independent Review Committee (IRC)-Assessed","description":"PFS was assessed as time to disease progression or death whichever occurred first by IRC assessment using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v1.1) Criteria. As per RECIST v1.1, disease progression is a 20% increase in the sum of the diameters of target lesions, an increase in size of measurable lesions by at least 5 mm and the appearance of new lesions.","populationDescription":"ITT population included all randomized participants in the study. Number of participants analyzed is the total participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Randomization to first documented disease progression or death, whichever occurs first (assessed every 8 weeks up to 33 months)","groups":[{"id":"OG000","title":"Alectinib","description":"Participants received alectinib at 600 mg orally BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death."},{"id":"OG001","title":"Crizotinib","description":"Participants received crizotinib at 250 mg orally BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"152"},{"groupId":"OG001","value":"151"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25.7","lowerLimit":"19.9","upperLimit":"NA","comment":"The upper limit of the CI could not be estimated in the alectinib arm at the time of data cutoff date (9 Feb 2017)."},{"groupId":"OG001","value":"10.4","lowerLimit":"7.7","upperLimit":"14.6"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","statisticalMethod":"Log Rank","statisticalComment":"Stratified hazard ratio and p-value are stratified for covariates Race (Asian vs Non-Asian) and CNS metastases at baseline by IRC.","paramType":"Hazard Ratio (HR)","paramValue":"0.50","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.36","ciUpperLimit":"0.70"}]},{"type":"SECONDARY","title":"Percentage of Participants With PFS Event by IRC","description":"PFS was assessed as percentage of participants with disease progression or death whichever occurred first by IRC assessment using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v1.1) Criteria. As per RECIST v1.1, disease progression is a 20% increase in the sum of the diameters of target lesions, an increase in size of measurable lesions by at least 5 mm and the appearance of new lesions.","populationDescription":"ITT population included all randomized participants in the study. Number of participants analyzed is the total participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of Participants","timeFrame":"Randomization to first documented disease progression or death, whichever occurs first (assessed every 8 weeks up to 33 months)","groups":[{"id":"OG000","title":"Alectinib","description":"Participants received alectinib at 600 mg orally BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death."},{"id":"OG001","title":"Crizotinib","description":"Participants received crizotinib at 250 mg orally BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"152"},{"groupId":"OG001","value":"151"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41.4"},{"groupId":"OG001","value":"60.9"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Central Nervous System (CNS) Progression as Determined by IRC Using RECIST V1.1 Criteria","description":"CNS progression was assessed as percentage of participants with an event defined as time from randomization until first radiographic evidence of CNS progression by IRC. The risk for a CNS progression without a prior non-CNS progression with alectinib compared with crizotinib.","populationDescription":"ITT population included all randomized participants in the study. Number of participants analyzed is the total participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of Participants","timeFrame":"Randomization to CNS PD as first occurrence of disease progression (assessed every 8 weeks up to 33 months)","groups":[{"id":"OG000","title":"Alectinib","description":"Participants received alectinib at 600 mg orally BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death."},{"id":"OG001","title":"Crizotinib","description":"Participants received crizotinib at 250 mg orally BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"152"},{"groupId":"OG001","value":"151"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.8"},{"groupId":"OG001","value":"45.0"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","nonInferiorityComment":"IRC, RECIST v1.1 Stratified Analysis (by race (Asian vs non-Asian) and CNS metastases at baseline by IRC)","pValue":"<0.0001","statisticalMethod":"Log Rank","paramType":"Cause-Specific Hazard Ratio","paramValue":"0.16","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.10","ciUpperLimit":"0.28"}]},{"type":"SECONDARY","title":"Percentage of Participants With Central Nervous System (CNS) Progression as Determined by IRC Using Revised Assessment in Neuro Oncology (RANO) Criteria","description":"CNS progression was assessed as percentage of participants with event defined as time from randomization until first radiographic evidence of CNS progression by IRC. The risk for a CNS progression without a prior non-CNS progression with alectinib compared with crizotinib.","populationDescription":"ITT population included all randomized participants in the study. Number of participants analyzed is the total participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of Participants","timeFrame":"Randomization to the first occurrence of disease progression in the CNS (assessed every 8 weeks up to 33 months)","groups":[{"id":"OG000","title":"Alectinib","description":"Participants received alectinib at 600 mg orally BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death."},{"id":"OG001","title":"Crizotinib","description":"Participants received crizotinib at 250 mg orally BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"152"},{"groupId":"OG001","value":"151"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.5"},{"groupId":"OG001","value":"35.8"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Objective Response Rate (ORR) of Complete Response (CR) or Partial Response (PR) as Determined by The Investigators According to RECIST V1.1 Criteria","description":"ORR was defined as the percentage of participants who attained CR or PR. As per RECIST v1.1, CR: Disappearance of all target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\< 10 mm, PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters.","populationDescription":"ITT population included all randomized participants in the study. Number of participants analyzed is the total participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of Participants","timeFrame":"Randomization to first documented disease progression or death, whichever occurs first (assessed every 8 weeks up to 33 months)","groups":[{"id":"OG000","title":"Alectinib","description":"Participants received alectinib at 600 mg orally BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death."},{"id":"OG001","title":"Crizotinib","description":"Participants received crizotinib at 250 mg orally BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"152"},{"groupId":"OG001","value":"151"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"82.9","lowerLimit":"75.95","upperLimit":"88.51"},{"groupId":"OG001","value":"75.5","lowerLimit":"67.84","upperLimit":"82.12"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0936","pValueComment":"Stratified analysis","statisticalMethod":"Mantel Haenszel","paramType":"Difference in Overall Response Rates","paramValue":"7.40","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-1.71","ciUpperLimit":"16.50"}]},{"type":"SECONDARY","title":"Duration of Response (DOR) According to RECIST V1.1 Criteria as Assessed by the Investigators","description":"DOR was defined as the time from when response (CR or PR) was first documented to first documented disease progression or death, whichever occurred first. DOR was evaluated for participants who had a best overall response (BOR) of CR or PR.","populationDescription":"ITT population included all participants randomized in the study, irrespective of whether or not they received study drug. Number analyzed indicates number of participants with a BOR of CR or PR.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"First occurrence of objective response to first documented disease progression or death, whichever occurs first (assessed every 8 weeks up to 33 months)","groups":[{"id":"OG000","title":"Alectinib","description":"Participants received alectinib at 600 mg orally BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death."},{"id":"OG001","title":"Crizotinib","description":"Participants received crizotinib at 250 mg orally BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"152"},{"groupId":"OG001","value":"151"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"The median DOR was not estimable \\[95% CI: NE\\] in the alectinib arm due to the low number of contributing events of disease progression or death."},{"groupId":"OG001","value":"11.1","lowerLimit":"7.9","upperLimit":"13.0"}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS)","description":"Overall survival (OS) was defined as the time from randomization to death from any cause.","populationDescription":"ITT population included all randomized participants in the study. Number of participants analyzed is the total participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"From randomization until death (up to 43 months)","groups":[{"id":"OG000","title":"Alectinib","description":"Participants received alectinib at 600 mg orally BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death."},{"id":"OG001","title":"Crizotinib","description":"Participants received crizotinib at 250 mg orally BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"152"},{"groupId":"OG001","value":"151"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Median time to OS event was not reached in participants in either treatment arm at the time of data cutoff (9 Feb 2017)."},{"groupId":"OG001","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Median time to OS event was not reached in participants in either treatment arm at the time of data cutoff (9 Feb 2017)."}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.2405","pValueComment":"Stratified analysis","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.76","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.48","ciUpperLimit":"1.20"}]},{"type":"SECONDARY","title":"Percentage of Participants With OS Event","description":"Overall survival (OS) was defined as the time from randomization to death from any cause.","populationDescription":"ITT population included all randomized participants in the study. Number of participants analyzed is the total participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of Participants","timeFrame":"From randomization until death (up to 43 months)","groups":[{"id":"OG000","title":"Alectinib","description":"Participants received alectinib at 600 mg orally BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death."},{"id":"OG001","title":"Crizotinib","description":"Participants received crizotinib at 250 mg orally BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"152"},{"groupId":"OG001","value":"151"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.0"},{"groupId":"OG001","value":"26.5"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With CNS ORR of CR or PR IRC-assessed According to RECIST v1.1 Criteria","description":"CNS ORR was defined as the percentage of participants who attained CR or PR and had measurable/non-measurable CNS lesions at baseline. As per RECIST v1.1, CR: Disappearance of all target lesions and any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\< 10 mm, PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters.","populationDescription":"ITT population included all randomized participants in the study. Number of participants analyzed is the total participants who were evaluable for this outcome measure (number of participants with measurable/non-measurable CNS lesions at baseline).","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of Participants","timeFrame":"Randomization to first documented disease progression or death, whichever occurs first (assessed every 8 weeks up to 33 months)","groups":[{"id":"OG000","title":"Alectinib","description":"Participants received alectinib at 600 mg orally BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death."},{"id":"OG001","title":"Crizotinib","description":"Participants received crizotinib at 250 mg orally BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"152"},{"groupId":"OG001","value":"151"}]}],"classes":[{"title":"Measurable CNS lesions at baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"22"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"81.0","lowerLimit":"58.09","upperLimit":"94.55"},{"groupId":"OG001","value":"50.0","lowerLimit":"28.22","upperLimit":"71.78"}]}]},{"title":"Measurable and non-measurable CNS lesions","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"58"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"59.4","lowerLimit":"46.37","upperLimit":"71.49"},{"groupId":"OG001","value":"25.9","lowerLimit":"15.26","upperLimit":"39.04"}]}]}]},{"type":"SECONDARY","title":"CNS DOR IRC-assessed According to RECIST v1.1 Criteria","description":"CNS DOR was defined as the time from when response (CR or PR) was first documented to first documented disease progression or death, whichever occurred first. DOR was evaluated for participants who had a best overall response (BOR) of CR or PR.","populationDescription":"ITT population included all participants randomized in the study, irrespective of whether or not they received study drug. Number analyzed indicates number of participants with a BOR of CR or PR.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"First occurrence of CNS objective response to first documented disease progression or death, whichever occurs first (assessed every 8 weeks up to 33 months)","groups":[{"id":"OG000","title":"Alectinib","description":"Participants received alectinib at 600 mg orally BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death."},{"id":"OG001","title":"Crizotinib","description":"Participants received crizotinib at 250 mg orally BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"22"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.3","lowerLimit":"14.8","upperLimit":"NA","comment":"The upper limit of the CI for CNS DOR could not be estimated at time of the data cutoff for participants in the alectinib arm."},{"groupId":"OG001","value":"5.5","lowerLimit":"2.1","upperLimit":"17.3"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Adverse Events","description":"An adverse event (AE) is any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.","populationDescription":"Safety (SAF) population included all participants who received at least one dose of any study drug.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of Participants","timeFrame":"Baseline up to 28 months in the crizotinib arm and up to 30 months in the alectinib arm","groups":[{"id":"OG000","title":"Alectinib","description":"Participants received alectinib at 600 mg orally BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death."},{"id":"OG001","title":"Crizotinib","description":"Participants received crizotinib at 250 mg orally BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"152"},{"groupId":"OG001","value":"151"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97.0"},{"groupId":"OG001","value":"97.0"}]}]}]},{"type":"SECONDARY","title":"Area Under The Concentration-Time Curve (AUC) of Alectinib","populationDescription":"The Pharmacokinetic (PK) Evaluable Population included all participants who received any dose of alectinib and who had at least one post-baseline PK sample available.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"hr*ng/mL","timeFrame":"Pre-dose (within 2 hours before alectinib) (baseline), 1, 2, 4, 6, and 8 hours post-dose at Visit 0 (first dosing day) and Week 4; Pre-dose (within 2 hours) at Week 8, then every 8 weeks until disease progression or death/withdrawal (up to 33 months)","groups":[{"id":"OG000","title":"Alectinib","description":"Participants received alectinib at 600 mg orally BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"144"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"713","spread":"104.9"}]}]},{"title":"Treatment - week 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5030","spread":"47.2"}]}]}]},{"type":"SECONDARY","title":"Maximum Concentration (Cmax) of Alectinib","populationDescription":"The Pharmacokinetic (PK) Evaluable Population included all participants who received any dose of alectinib and who had at least one post-baseline PK sample available.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"nanogram/milliliter (ng/mL)","timeFrame":"Pre-dose (within 2 hours before alectinib), 1, 2, 4, 6, and 8 hours post-dose at baseline and Week 4; Pre-dose (within 2 hours before alectinib) at Week 8, then every 8 weeks until disease progression or death/withdrawal from study (up to 33 months)","groups":[{"id":"OG000","title":"Alectinib","description":"Participants received alectinib at 600 mg orally BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"144"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"211","spread":"55.5"}]}]},{"title":"Treatment - week 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"717","spread":"46.8"}]}]}]},{"type":"SECONDARY","title":"Time to Reach Cmax (Tmax) of Alectinib","populationDescription":"The Pharmacokinetic (PK) Evaluable Population included all participants who received any dose of alectinib and who had at least one post-baseline PK sample available.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"hours","timeFrame":"Pre-dose (within 2 hours before alectinib), 1, 2, 4, 6, and 8 hours post-dose at baseline and Week 4; Pre-dose (within 2 hours before alectinib) at Week 8, then every 8 weeks until disease progression or death/withdrawal from study (up to 33 months)","groups":[{"id":"OG000","title":"Alectinib","description":"Participants received alectinib at 600 mg orally BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"144"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.03","lowerLimit":"1.98","upperLimit":"12.00"}]}]},{"title":"Treatment - week 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4.02","lowerLimit":"2.00","upperLimit":"8.00"}]}]}]},{"type":"SECONDARY","title":"AUC of Alectinib Metabolite","populationDescription":"The Pharmacokinetic (PK) Evaluable Population included all participants who received any dose of alectinib and who had at least one post-baseline PK sample available.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"hr*ng/mL","timeFrame":"Pre-dose (within 2 hours before alectinib) (baseline), 1, 2, 4, 6, and 8 hours post-dose at Visit 0 (first dosing day) and Week 4; Pre-dose (within 2 hours) at Week 8, then every 8 weeks until disease progression or death/withdrawal (up to 33 months)","groups":[{"id":"OG000","title":"Alectinib","description":"Participants received alectinib at 600 mg orally BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"144"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"142","spread":"191.7"}]}]},{"title":"Treatment - week 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2230","spread":"37.0"}]}]}]},{"type":"SECONDARY","title":"Cmax of Alectinib Metabolite","populationDescription":"The Pharmacokinetic (PK) Evaluable Population included all participants who received any dose of alectinib and who had at least one post-baseline PK sample available.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","unitOfMeasure":"nanogram/milliliter (ng/mL)","timeFrame":"Pre-dose (within 2 hours before alectinib), 1, 2, 4, 6, and 8 hours post-dose at baseline and Week 4; Pre-dose (within 2 hours before alectinib) at Week 8, then every 8 weeks until disease progression or death/withdrawal from study (up to 33 months)","groups":[{"id":"OG000","title":"Alectinib","description":"Participants received alectinib at 600 mg orally BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"144"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"56.2","spread":"80.1"}]}]},{"title":"Treatment - week 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"321","spread":"32.0"}]}]}]},{"type":"SECONDARY","title":"Tmax of Alectinib Metabolite","populationDescription":"The Pharmacokinetic (PK) Evaluable Population included all participants who received any dose of alectinib and who had at least one post-baseline PK sample available.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"hours","timeFrame":"Pre-dose (within 2 hours before alectinib), 1, 2, 4, 6, and 8 hours post-dose at baseline and Week 4; Pre-dose (within 2 hours before alectinib) at Week 8, then every 8 weeks until disease progression or death/withdrawal from study (up to 33 months)","groups":[{"id":"OG000","title":"Alectinib","description":"Participants received alectinib at 600 mg orally BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"144"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.00","lowerLimit":"5.98","upperLimit":"12.00"}]}]},{"title":"Treatment - week 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6.00","lowerLimit":"2.00","upperLimit":"10.00"}]}]}]},{"type":"SECONDARY","title":"Time to Deterioration by European Organization for The Research And Treatment of Cancer (EORTC) Quality Of Life Questionnaire Core 30 (C30)","description":"The EORTC QLQ-30 module generated one multiple-item scale score assessing dyspnea and a series of single item scores assessing chest pain, arm/shoulder pain, pain in other parts, coughing, sore mouth, dysphagia, peripheral neuropathy, alopecia, and hemoptysis. All the scales and single-item scores were linearly transformed so that each score ranged from 0 to 100. A higher score on the global health and functioning subscales is indicative of better functioning. Confirmed clinically meaningful deterioration in global health status or function is defined as a \\>or=10-point decrease from baseline in a symptom score that must be held for at least two consecutive assessments or an initial \\>or=10-point decrease from baseline followed by death within 5 weeks from the last assessment.","populationDescription":"ITT population included all randomized participants in the study. Number of participants analyzed is the total participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Baseline, every 4 weeks until disease progression (up to 33 months)","groups":[{"id":"OG000","title":"Alectinib","description":"Participants received alectinib at 600 mg orally BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death."},{"id":"OG001","title":"Crizotinib","description":"Participants received crizotinib at 250 mg orally BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"152"},{"groupId":"OG001","value":"151"}]}],"classes":[{"title":"Fatigue","categories":[{"measurements":[{"groupId":"OG000","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Median deterioration not reached at CCOD"},{"groupId":"OG001","value":"NA","lowerLimit":"9.4","upperLimit":"NA","comment":"Median deterioration not reached at CCOD"}]}]},{"title":"Dyspnea","categories":[{"measurements":[{"groupId":"OG000","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Median deterioration not reached at CCOD"},{"groupId":"OG001","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Median deterioration not reached at CCOD"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Fatigue","nonInferiorityType":"SUPERIORITY","pValue":"0.2079","statisticalMethod":"Log Rank","statisticalComment":"Stratified analysis","paramType":"Hazard Ratio (HR)","paramValue":"0.74","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.46","ciUpperLimit":"1.19"},{"groupIds":["OG000","OG001"],"groupDescription":"Dyspnea","nonInferiorityType":"SUPERIORITY","pValue":"0.1137","pValueComment":"Stratified analysis","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"1.66","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.88","ciUpperLimit":"3.15"}]},{"type":"SECONDARY","title":"Percentage of Participants With Deterioration by EORTC Quality Of Life Questionnaire Core 30 (C30)","description":"The EORTC QLQ-30 module generated one multiple-item scale score assessing dyspnea and a series of single item scores assessing chest pain, arm/shoulder pain, pain in other parts, coughing, sore mouth, dysphagia, peripheral neuropathy, alopecia, and hemoptysis. All the scales and single-item scores were linearly transformed so that each score ranged from 0 to 100. A higher score on the global health and functioning subscales is indicative of better functioning. Confirmed clinically meaningful deterioration in global health status or function is defined as a \\>or=10-point decrease from baseline in a symptom score that must be held for at least two consecutive assessments or an initial \\>or=10-point decrease from baseline followed by death within 5 weeks from the last assessment.","populationDescription":"ITT population included all randomized participants in the study. Number of participants analyzed is the total participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of Participants","timeFrame":"Baseline, every 4 weeks until disease progression (up to 33 months)","groups":[{"id":"OG000","title":"Alectinib","description":"Participants received alectinib at 600 mg orally BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death."},{"id":"OG001","title":"Crizotinib","description":"Participants received crizotinib at 250 mg orally BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"152"},{"groupId":"OG001","value":"151"}]}],"classes":[{"title":"Fatigue","categories":[{"measurements":[{"groupId":"OG000","value":"21.7"},{"groupId":"OG001","value":"25.2"}]}]},{"title":"Dyspnea","categories":[{"measurements":[{"groupId":"OG000","value":"17.1"},{"groupId":"OG001","value":"9.9"}]}]}]},{"type":"SECONDARY","title":"Time to Deterioration by EORTC Quality of Life Questionnaire Lung Cancer Module 13 (LC13)","description":"The EORTC QLQ-LC13 module generated one multiple-item scale score assessing dyspnea and a series of single item scores assessing chest pain, arm/shoulder pain, pain in other parts, coughing, sore mouth, dysphagia, peripheral neuropathy, alopecia, and hemoptysis. All the scales and single-item scores were linearly transformed so that each score ranged from 0 to 100. A higher score on the global health and functioning subscales is indicative of better functioning. Confirmed clinically meaningful deterioration in lung cancer symptoms is defined as a \\>or=10-point increase from baseline in a symptom score that must be held for at least two consecutive assessments or an initial \\>or=10-point increase above baseline followed by death within 5 weeks from the last assessment.","populationDescription":"ITT population included all randomized participants in the study. Number of participants analyzed is the total participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Baseline, every 4 weeks until disease progression (up to 33 months)","groups":[{"id":"OG000","title":"Alectinib","description":"Participants received alectinib at 600 mg orally BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death."},{"id":"OG001","title":"Crizotinib","description":"Participants received crizotinib at 250 mg orally BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"152"},{"groupId":"OG001","value":"151"}]}],"classes":[{"title":"Coughing","categories":[{"measurements":[{"groupId":"OG000","value":"NA","lowerLimit":"24.0","upperLimit":"NA","comment":"Median deterioration not reached at CCOD"},{"groupId":"OG001","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Median deterioration not reached at CCOD"}]}]},{"title":"Dyspnea","categories":[{"measurements":[{"groupId":"OG000","value":"22.8","lowerLimit":"11.8","upperLimit":"NA","comment":"Upper limit of the CI not reached at CCOD"},{"groupId":"OG001","value":"NA","lowerLimit":"21.0","upperLimit":"NA","comment":"Median deterioration not reached at CCOD"}]}]},{"title":"Pain in arm and shoulder","categories":[{"measurements":[{"groupId":"OG000","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Median deterioration not reached at CCOD"},{"groupId":"OG001","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Median deterioration not reached at CCOD"}]}]},{"title":"Pain in chest","categories":[{"measurements":[{"groupId":"OG000","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Median deterioration not reached at CCOD"},{"groupId":"OG001","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Median deterioration not reached at CCOD"}]}]},{"title":"Composite score (c, p in c, d)","categories":[{"measurements":[{"groupId":"OG000","value":"12.7","lowerLimit":"5.0","upperLimit":"NA","comment":"Upper limit of the CI not reached at CCOD"},{"groupId":"OG001","value":"21.0","lowerLimit":"9.8","upperLimit":"NA","comment":"Upper limit of the CI not reached at CCOD"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Coughing","nonInferiorityType":"SUPERIORITY","pValue":"0.7042","pValueComment":"Stratified analysis","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.88","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.44","ciUpperLimit":"1.74"},{"groupIds":["OG000","OG001"],"groupDescription":"Dyspnea","nonInferiorityType":"SUPERIORITY","pValue":"0.0285","pValueComment":"Stratified analysis","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"1.76","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.05","ciUpperLimit":"2.92"},{"groupIds":["OG000","OG001"],"groupDescription":"Pain in arm and shoulder","nonInferiorityType":"SUPERIORITY","pValue":"0.2377","pValueComment":"Stratified analysis","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"1.43","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.79","ciUpperLimit":"2.61"},{"groupIds":["OG000","OG001"],"groupDescription":"Pain in chest","nonInferiorityType":"SUPERIORITY","pValue":"0.0796","pValueComment":"Stratified analysis","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.51","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.24","ciUpperLimit":"1.10"},{"groupIds":["OG000","OG001"],"groupDescription":"Composite score","nonInferiorityType":"SUPERIORITY","pValue":"0.6435","pValueComment":"Stratified analysis","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"1.10","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.72","ciUpperLimit":"1.68"}]},{"type":"SECONDARY","title":"Percentage of Participants With Deterioration by EORTC Quality of Life Questionnaire Lung Cancer Module 13 (LC13)","description":"The EORTC QLQ-LC13 module generated one multiple-item scale score assessing dyspnea and a series of single item scores assessing chest pain, arm/shoulder pain, pain in other parts, coughing, sore mouth, dysphagia, peripheral neuropathy, alopecia, and hemoptysis. All the scales and single-item scores were linearly transformed so that each score ranged from 0 to 100. A higher score on the global health and functioning subscales is indicative of better functioning. Confirmed clinically meaningful deterioration in lung cancer symptoms is defined as a \\>or=10-point increase from baseline in a symptom score that must be held for at least two consecutive assessments or an initial \\>or=10-point increase above baseline followed by death within 5 weeks from the last assessment.","populationDescription":"ITT population included all randomized participants in the study. Number of participants analyzed is the total participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of Participants","timeFrame":"Baseline, every 4 weeks until disease progression (up to 33 months)","groups":[{"id":"OG000","title":"Alectinib","description":"Participants received alectinib at 600 mg orally BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death."},{"id":"OG001","title":"Crizotinib","description":"Participants received crizotinib at 250 mg orally BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"152"},{"groupId":"OG001","value":"151"}]}],"classes":[{"title":"Coughing","categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"11"}]}]},{"title":"Dyspnea","categories":[{"measurements":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"16"}]}]},{"title":"Pain in arm and shoulder","categories":[{"measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"12"}]}]},{"title":"Pain in chest","categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"11"}]}]},{"title":"Composite score (c, p in c, d)","categories":[{"measurements":[{"groupId":"OG000","value":"32"},{"groupId":"OG001","value":"28"}]}]}]},{"type":"SECONDARY","title":"Health-Related Quality of Life (HRQoL) by EORTC Quality of Life Questionnaire C30 Score","description":"The EORTC QLQ-C30 questionnaire consisted of 30 questions generating five functional scores (physical, role, cognitive, emotional, and social); a global health status/global quality of life scale score; three symptom scale scores (fatigue, pain, and nausea and vomiting); and six stand alone one-item scores that capture additional symptoms (dyspnea, appetite loss, sleep disturbance, constipation, and diarrhea) and perceived financial burden. All the scales and single-item scores were linearly transformed so that each score ranged from 0 to 100. A higher score on the global health and functioning subscales is indicative of better functioning.","populationDescription":"ITT population included all participants randomized in the study, irrespective of whether or not they received study drug. Number analyzed indicates number of participants evaluated for specified time points.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"Score on a scale","timeFrame":"Baseline, every 4 weeks until disease progression (up to 33 months)","groups":[{"id":"OG000","title":"Alectinib","description":"Participants received alectinib at 600 mg orally BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death."},{"id":"OG001","title":"Crizotinib","description":"Participants received crizotinib at 250 mg orally BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"152"},{"groupId":"OG001","value":"151"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"100"},{"groupId":"OG001","value":"97"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"66.67","lowerLimit":"8.3","upperLimit":"100.0"},{"groupId":"OG001","value":"66.67","lowerLimit":"0.0","upperLimit":"100.0"}]}]},{"title":"Treatment - week 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"95"},{"groupId":"OG001","value":"89"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"66.67","lowerLimit":"0.0","upperLimit":"100.0"},{"groupId":"OG001","value":"66.67","lowerLimit":"16.7","upperLimit":"100.0"}]}]},{"title":"Treatment - week 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"89"},{"groupId":"OG001","value":"84"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"75.0","lowerLimit":"16.7","upperLimit":"100.0"},{"groupId":"OG001","value":"75.0","lowerLimit":"16.7","upperLimit":"100.0"}]}]},{"title":"Treatment - week 12","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"75"},{"groupId":"OG001","value":"78"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"75.0","lowerLimit":"25.0","upperLimit":"100.0"},{"groupId":"OG001","value":"75.0","lowerLimit":"33.3","upperLimit":"100.0"}]}]},{"title":"Treatment - week 16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"73"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"75.0","lowerLimit":"16.7","upperLimit":"100.0"},{"groupId":"OG001","value":"83.33","lowerLimit":"16.7","upperLimit":"100.0"}]}]},{"title":"Treatment - week 20","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"67"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"75.0","lowerLimit":"16.7","upperLimit":"100.0"},{"groupId":"OG001","value":"75.0","lowerLimit":"16.7","upperLimit":"100.0"}]}]},{"title":"Treatment - week 24","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"77"},{"groupId":"OG001","value":"71"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"75.0","lowerLimit":"16.7","upperLimit":"100.0"},{"groupId":"OG001","value":"83.33","lowerLimit":"8.3","upperLimit":"100.0"}]}]},{"title":"Treatment - week 28","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"62"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"75.0","lowerLimit":"33.3","upperLimit":"100.0"},{"groupId":"OG001","value":"75.0","lowerLimit":"33.3","upperLimit":"100.0"}]}]},{"title":"Treatment - week 32","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"65"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"75.0","lowerLimit":"33.3","upperLimit":"100.0"},{"groupId":"OG001","value":"66.67","lowerLimit":"8.3","upperLimit":"100.0"}]}]},{"title":"Treatment - week 36","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"61"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"79.17","lowerLimit":"16.7","upperLimit":"100.0"},{"groupId":"OG001","value":"66.67","lowerLimit":"16.7","upperLimit":"100.0"}]}]},{"title":"Treatment - week 40","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"74"},{"groupId":"OG001","value":"50"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"75.0","lowerLimit":"16.7","upperLimit":"100.0"},{"groupId":"OG001","value":"83.33","lowerLimit":"33.3","upperLimit":"100.0"}]}]},{"title":"Treatment - week 44","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"62"},{"groupId":"OG001","value":"47"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"83.33","lowerLimit":"16.7","upperLimit":"100.0"},{"groupId":"OG001","value":"83.33","lowerLimit":"16.7","upperLimit":"100.0"}]}]},{"title":"Treatment - week 48","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"47"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"66.67","lowerLimit":"25.0","upperLimit":"100.0"},{"groupId":"OG001","value":"83.33","lowerLimit":"41.7","upperLimit":"100.0"}]}]},{"title":"Treatment - week 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"44"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"83.33","lowerLimit":"16.7","upperLimit":"100.0"},{"groupId":"OG001","value":"75.00","lowerLimit":"41.7","upperLimit":"100.0"}]}]},{"title":"Treatment - week 56","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"61"},{"groupId":"OG001","value":"48"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"75.0","lowerLimit":"16.7","upperLimit":"100.0"},{"groupId":"OG001","value":"75.0","lowerLimit":"41.7","upperLimit":"100.0"}]}]},{"title":"Treatment - week 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"47"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"75.0","lowerLimit":"33.3","upperLimit":"100.0"},{"groupId":"OG001","value":"75.0","lowerLimit":"50.0","upperLimit":"100.0"}]}]},{"title":"Treatment - week 64","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"55"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"75.0","lowerLimit":"33.3","upperLimit":"100.0"},{"groupId":"OG001","value":"83.33","lowerLimit":"41.7","upperLimit":"100.0"}]}]},{"title":"Treatment - week 68","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"34"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"75.0","lowerLimit":"33.3","upperLimit":"100.0"},{"groupId":"OG001","value":"79.17","lowerLimit":"33.3","upperLimit":"100.0"}]}]},{"title":"Treatment - week 72","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"34"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"75.0","lowerLimit":"33.3","upperLimit":"100.0"},{"groupId":"OG001","value":"75.00","lowerLimit":"8.3","upperLimit":"100.0"}]}]},{"title":"Treatment - week 76","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"75.0","lowerLimit":"41.7","upperLimit":"100.0"},{"groupId":"OG001","value":"75.0","lowerLimit":"16.7","upperLimit":"100.0"}]}]},{"title":"Treatment - week 80","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"23"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"75.0","lowerLimit":"33.3","upperLimit":"100.0"},{"groupId":"OG001","value":"75.0","lowerLimit":"33.3","upperLimit":"100.0"}]}]},{"title":"Treatment - week 84","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"19"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"83.33","lowerLimit":"41.7","upperLimit":"100.0"},{"groupId":"OG001","value":"66.67","lowerLimit":"33.3","upperLimit":"100.0"}]}]},{"title":"Treatment - week 88","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"16"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"75.0","lowerLimit":"33.3","upperLimit":"100.0"},{"groupId":"OG001","value":"66.67","lowerLimit":"33.3","upperLimit":"100.0"}]}]},{"title":"Treatment - week 92","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"70.83","lowerLimit":"33.3","upperLimit":"100.0"},{"groupId":"OG001","value":"75.0","lowerLimit":"50.0","upperLimit":"100.0"}]}]},{"title":"Treatment - week 96","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"66.67","lowerLimit":"33.3","upperLimit":"100.0"},{"groupId":"OG001","value":"66.67","lowerLimit":"33.3","upperLimit":"100.0"}]}]},{"title":"Treatment - week 100","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"66.67","lowerLimit":"25.0","upperLimit":"100.0"},{"groupId":"OG001","value":"75.0","lowerLimit":"33.3","upperLimit":"100.0"}]}]},{"title":"Treatment - week 104","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"66.67","lowerLimit":"50.0","upperLimit":"100.0"},{"groupId":"OG001","value":"66.67","lowerLimit":"50.0","upperLimit":"100.0"}]}]},{"title":"Treatment - week 108","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"66.67","lowerLimit":"50.0","upperLimit":"100.0"},{"groupId":"OG001","value":"75.0","lowerLimit":"33.3","upperLimit":"100.0"}]}]},{"title":"Treatment - week 112","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"75.0","lowerLimit":"50.0","upperLimit":"100.0"},{"groupId":"OG001","value":"75.0","lowerLimit":"33.3","upperLimit":"100.0"}]}]},{"title":"Treatment - week 116","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"70.83","lowerLimit":"41.7","upperLimit":"100.0"},{"groupId":"OG001","value":"91.67","lowerLimit":"83.3","upperLimit":"100.0"}]}]},{"title":"Treatment - week 120","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"151"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"83.3","lowerLimit":"50.0","upperLimit":"100.0"},{"groupId":"OG001","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Not evaluable at week 120"}]}]}]},{"type":"SECONDARY","title":"HRQoL by EORTC Quality of Life Questionnaire LC13 Score Coughing","description":"The EORTC QLQ-LC13 module generated one multiple-item scale score assessing dyspnea and a series of single item scores assessing chest pain, arm/shoulder pain, pain in other parts, coughing, sore mouth, dysphagia, peripheral neuropathy, alopecia, and hemoptysis. All the scales and single-item scores were linearly transformed so that each score ranged from 0 to 100. A higher score on the global health and functioning subscales is indicative of better functioning.","populationDescription":"ITT population included all participants randomized in the study, irrespective of whether or not they received study drug. Number analyzed indicates number of participants evaluated for specified time points.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"Score on a scale","timeFrame":"Baseline, every 4 weeks until disease progression (up to 33 months)","groups":[{"id":"OG000","title":"Alectinib","description":"Participants received alectinib at 600 mg orally BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death."},{"id":"OG001","title":"Crizotinib","description":"Participants received crizotinib at 250 mg orally BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"152"},{"groupId":"OG001","value":"151"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"100"},{"groupId":"OG001","value":"96"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"33.33","lowerLimit":"0.0","upperLimit":"100.0"},{"groupId":"OG001","value":"33.33","lowerLimit":"0.0","upperLimit":"100.0"}]}]},{"title":"Treatment - week 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"95"},{"groupId":"OG001","value":"89"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"33.33","lowerLimit":"0.0","upperLimit":"100.0"},{"groupId":"OG001","value":"33.33","lowerLimit":"0.0","upperLimit":"100.0"}]}]},{"title":"Treatment - week 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"89"},{"groupId":"OG001","value":"84"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"33.33","lowerLimit":"0.0","upperLimit":"66.7"},{"groupId":"OG001","value":"33.33","lowerLimit":"0.0","upperLimit":"100.0"}]}]},{"title":"Treatment - week 12","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"75"},{"groupId":"OG001","value":"78"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"33.33","lowerLimit":"0.0","upperLimit":"100.0"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"66.7"}]}]},{"title":"Treatment - week 16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"73"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"100.0"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"66.7"}]}]},{"title":"Treatment - week 20","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"67"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"33.33","lowerLimit":"0.0","upperLimit":"100.0"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"66.7"}]}]},{"title":"Treatment - week 24","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"77"},{"groupId":"OG001","value":"71"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"33.33","lowerLimit":"0.0","upperLimit":"100.0"},{"groupId":"OG001","value":"33.33","lowerLimit":"0.0","upperLimit":"100.0"}]}]},{"title":"Treatment - week 28","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"62"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"33.33","lowerLimit":"0.0","upperLimit":"100.0"},{"groupId":"OG001","value":"16.67","lowerLimit":"0.0","upperLimit":"100.0"}]}]},{"title":"Treatment - week 32","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"65"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"33.33","lowerLimit":"0.0","upperLimit":"100.0"},{"groupId":"OG001","value":"33.33","lowerLimit":"0.0","upperLimit":"100.0"}]}]},{"title":"Treatment - week 36","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"61"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"100.0"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"66.7"}]}]},{"title":"Treatment - week 40","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"74"},{"groupId":"OG001","value":"50"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"33.33","lowerLimit":"0.0","upperLimit":"66.7"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"66.7"}]}]},{"title":"Treatment - week 44","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"62"},{"groupId":"OG001","value":"47"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"66.7"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"66.7"}]}]},{"title":"Treatment - week 48","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"47"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"33.33","lowerLimit":"0.0","upperLimit":"66.7"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"66.7"}]}]},{"title":"Treatment - week 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"44"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"66.7"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"33.3"}]}]},{"title":"Treatment - week 56","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"61"},{"groupId":"OG001","value":"48"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"66.7"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"100.0"}]}]},{"title":"Treatment - week 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"47"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"33.33","lowerLimit":"0.0","upperLimit":"100.0"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"66.7"}]}]},{"title":"Treatment - week 64","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"55"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"33.33","lowerLimit":"0.0","upperLimit":"66.7"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"66.7"}]}]},{"title":"Treatment - week 68","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"34"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"33.33","lowerLimit":"0.0","upperLimit":"66.7"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"66.7"}]}]},{"title":"Treatment - week 72","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"34"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"66.7"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"66.7"}]}]},{"title":"Treatment - week 76","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"66.7"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"66.7"}]}]},{"title":"Treatment - week 80","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"23"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"33.33","lowerLimit":"0.0","upperLimit":"66.7"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"33.33"}]}]},{"title":"Treatment - week 84","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"19"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"66.7"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"33.33"}]}]},{"title":"Treatment - week 88","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"16"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"33.33","lowerLimit":"0.0","upperLimit":"100.0"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"33.33"}]}]},{"title":"Treatment - week 92","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"66.7"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"66.7"}]}]},{"title":"Treatment - week 96","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"16.67","lowerLimit":"0.0","upperLimit":"66.7"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"33.33"}]}]},{"title":"Treatment - week 100","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"100.0"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"33.3"}]}]},{"title":"Treatment - week 104","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"33.33","lowerLimit":"0.0","upperLimit":"66.7"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"33.3"}]}]},{"title":"Treatment - week 108","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"33.33","lowerLimit":"0.0","upperLimit":"66.7"},{"groupId":"OG001","value":"33.33","lowerLimit":"0.0","upperLimit":"33.33"}]}]},{"title":"Treatment - week 112","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"33.33","lowerLimit":"0.0","upperLimit":"33.33"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"33.33"}]}]},{"title":"Treatment - week 116","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"33.33","lowerLimit":"0.0","upperLimit":"33.33"},{"groupId":"OG001","value":"16.67","lowerLimit":"0.0","upperLimit":"33.33"}]}]},{"title":"Treatment - week 120","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"33.33","lowerLimit":"33.33","upperLimit":"33.33"}]}]}]},{"type":"SECONDARY","title":"HRQoL by EORTC Quality of Life Questionnaire LC13 Score Dyspnoea","description":"The EORTC QLQ-LC13 module generated one multiple-item scale score assessing dyspnea and a series of single item scores assessing chest pain, arm/shoulder pain, pain in other parts, coughing, sore mouth, dysphagia, peripheral neuropathy, alopecia, and hemoptysis. All the scales and single-item scores were linearly transformed so that each score ranged from 0 to 100. A higher score on the global health and functioning subscales is indicative of better functioning.","populationDescription":"ITT population included all participants randomized in the study, irrespective of whether or not they received study drug. Number analyzed indicates number of participants evaluated for specified time points.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"Score on a scale","timeFrame":"Baseline, every 4 weeks until disease progression (up to 33 months)","groups":[{"id":"OG000","title":"Alectinib","description":"Participants received alectinib at 600 mg orally BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death."},{"id":"OG001","title":"Crizotinib","description":"Participants received crizotinib at 250 mg orally BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"152"},{"groupId":"OG001","value":"151"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"100"},{"groupId":"OG001","value":"96"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"22.22","lowerLimit":"0.0","upperLimit":"100.0"},{"groupId":"OG001","value":"22.22","lowerLimit":"0.0","upperLimit":"100.0"}]}]},{"title":"Treatment - Week 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"95"},{"groupId":"OG001","value":"89"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"22.22","lowerLimit":"0.0","upperLimit":"100.0"},{"groupId":"OG001","value":"22.22","lowerLimit":"0.0","upperLimit":"88.9"}]}]},{"title":"Treatment - Week 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"89"},{"groupId":"OG001","value":"84"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"22.22","lowerLimit":"0.0","upperLimit":"66.7"},{"groupId":"OG001","value":"11.11","lowerLimit":"0.0","upperLimit":"66.7"}]}]},{"title":"Treatment - Week 12","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"75"},{"groupId":"OG001","value":"78"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"22.22","lowerLimit":"0.0","upperLimit":"66.7"},{"groupId":"OG001","value":"11.11","lowerLimit":"0.0","upperLimit":"66.7"}]}]},{"title":"Treatment - Week 16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"73"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"22.22","lowerLimit":"0.0","upperLimit":"77.8"},{"groupId":"OG001","value":"11.11","lowerLimit":"0.0","upperLimit":"88.9"}]}]},{"title":"Treatment - Week 20","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"67"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"22.22","lowerLimit":"0.0","upperLimit":"88.9"},{"groupId":"OG001","value":"11.11","lowerLimit":"0.0","upperLimit":"66.7"}]}]},{"title":"Treatment - Week 24","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"77"},{"groupId":"OG001","value":"71"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"22.22","lowerLimit":"0.0","upperLimit":"77.8"},{"groupId":"OG001","value":"11.11","lowerLimit":"0.0","upperLimit":"77.8"}]}]},{"title":"Treatment - Week 28","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"62"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11.11","lowerLimit":"0.0","upperLimit":"44.4"},{"groupId":"OG001","value":"11.11","lowerLimit":"0.0","upperLimit":"100.0"}]}]},{"title":"Treatment - Week 32","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"65"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"22.22","lowerLimit":"0.0","upperLimit":"66.7"},{"groupId":"OG001","value":"11.11","lowerLimit":"0.0","upperLimit":"88.9"}]}]},{"title":"Treatment - Week 36","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"61"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"16.67","lowerLimit":"0.0","upperLimit":"77.8"},{"groupId":"OG001","value":"11.11","lowerLimit":"0.0","upperLimit":"66.7"}]}]},{"title":"Treatment - Week 40","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"74"},{"groupId":"OG001","value":"50"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11.11","lowerLimit":"0.0","upperLimit":"55.6"},{"groupId":"OG001","value":"5.56","lowerLimit":"0.0","upperLimit":"66.7"}]}]},{"title":"Treatment - Week 44","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"62"},{"groupId":"OG001","value":"47"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11.11","lowerLimit":"0.0","upperLimit":"88.9"},{"groupId":"OG001","value":"11.11","lowerLimit":"0.0","upperLimit":"77.8"}]}]},{"title":"Treatment - Week 48","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"47"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"22.22","lowerLimit":"0.0","upperLimit":"55.6"},{"groupId":"OG001","value":"11.11","lowerLimit":"0.0","upperLimit":"44.4"}]}]},{"title":"Treatment - Week 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"44"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"22.22","lowerLimit":"0.0","upperLimit":"44.4"},{"groupId":"OG001","value":"11.11","lowerLimit":"0.0","upperLimit":"66.7"}]}]},{"title":"Treatment - Week 56","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"61"},{"groupId":"OG001","value":"48"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"22.22","lowerLimit":"0.0","upperLimit":"77.8"},{"groupId":"OG001","value":"11.11","lowerLimit":"0.0","upperLimit":"77.8"}]}]},{"title":"Treatment - Week 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"47"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"22.22","lowerLimit":"0.0","upperLimit":"77.8"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"55.6"}]}]},{"title":"Treatment - Week 64","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"55"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"22.22","lowerLimit":"0.0","upperLimit":"66.7"},{"groupId":"OG001","value":"11.11","lowerLimit":"0.0","upperLimit":"66.7"}]}]},{"title":"Treatment - Week 68","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"34"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"22.22","lowerLimit":"0.0","upperLimit":"77.8"},{"groupId":"OG001","value":"11.11","lowerLimit":"0.0","upperLimit":"55.6"}]}]},{"title":"Treatment - Week 72","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"34"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"22.22","lowerLimit":"0.0","upperLimit":"66.7"},{"groupId":"OG001","value":"11.11","lowerLimit":"0.0","upperLimit":"44.4"}]}]},{"title":"Treatment - Week 76","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11.11","lowerLimit":"0.0","upperLimit":"66.7"},{"groupId":"OG001","value":"11.11","lowerLimit":"0.0","upperLimit":"55.6"}]}]},{"title":"Treatment - Week 80","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"23"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"22.22","lowerLimit":"0.0","upperLimit":"66.7"},{"groupId":"OG001","value":"11.11","lowerLimit":"0.0","upperLimit":"55.6"}]}]},{"title":"Treatment - Week 84","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"19"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11.11","lowerLimit":"0.0","upperLimit":"66.7"},{"groupId":"OG001","value":"11.11","lowerLimit":"0.0","upperLimit":"44.4"}]}]},{"title":"Treatment - Week 88","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"16"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"22.22","lowerLimit":"0.0","upperLimit":"55.6"},{"groupId":"OG001","value":"22.22","lowerLimit":"0.0","upperLimit":"33.3"}]}]},{"title":"Treatment - Week 92","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"22.22","lowerLimit":"0.0","upperLimit":"44.4"},{"groupId":"OG001","value":"22.22","lowerLimit":"0.0","upperLimit":"77.8"}]}]},{"title":"Treatment - Week 96","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"22.22","lowerLimit":"0.0","upperLimit":"66.7"},{"groupId":"OG001","value":"22.22","lowerLimit":"0.0","upperLimit":"44.4"}]}]},{"title":"Treatment - Week 100","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"22.22","lowerLimit":"0.0","upperLimit":"55.6"},{"groupId":"OG001","value":"27.78","lowerLimit":"0.0","upperLimit":"44.4"}]}]},{"title":"Treatment - Week 104","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11.11","lowerLimit":"0.0","upperLimit":"66.7"},{"groupId":"OG001","value":"11.11","lowerLimit":"0.0","upperLimit":"33.3"}]}]},{"title":"Treatment - Week 108","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"22.22","lowerLimit":"0.0","upperLimit":"66.7"},{"groupId":"OG001","value":"11.11","lowerLimit":"0.0","upperLimit":"33.3"}]}]},{"title":"Treatment - Week 112","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11.11","lowerLimit":"11.11","upperLimit":"44.4"},{"groupId":"OG001","value":"27.78","lowerLimit":"0.0","upperLimit":"33.3"}]}]},{"title":"Treatment - Week 116","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"16.67","lowerLimit":"11.1","upperLimit":"22.2"},{"groupId":"OG001","value":"16.67","lowerLimit":"0.0","upperLimit":"33.3"}]}]},{"title":"Treatment - Week 120","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"22.22","lowerLimit":"11.1","upperLimit":"33.3"}]}]}]},{"type":"SECONDARY","title":"HRQoL by EORTC Quality of Life Questionnaire LC13 Score Pain in Chest","description":"The EORTC QLQ-LC13 module generated one multiple-item scale score assessing dyspnea and a series of single item scores assessing chest pain, arm/shoulder pain, pain in other parts, coughing, sore mouth, dysphagia, peripheral neuropathy, alopecia, and hemoptysis. All the scales and single-item scores were linearly transformed so that each score ranged from 0 to 100. A higher score on the global health and functioning subscales is indicative of better functioning.","populationDescription":"ITT population included all participants randomized in the study, irrespective of whether or not they received study drug. Number analyzed indicates number of participants evaluated for specified time points.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"Score on a scale","timeFrame":"Baseline, every 4 weeks until disease progression (up to 33 months)","groups":[{"id":"OG000","title":"Alectinib","description":"Participants received alectinib at 600 mg orally BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death."},{"id":"OG001","title":"Crizotinib","description":"Participants received crizotinib at 250 mg orally BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"152"},{"groupId":"OG001","value":"151"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"100"},{"groupId":"OG001","value":"96"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"33.33","lowerLimit":"0.0","upperLimit":"100.0"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"100.0"}]}]},{"title":"Treatment - Week 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"95"},{"groupId":"OG001","value":"89"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"66.7"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"66.7"}]}]},{"title":"Treatment - Week 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"89"},{"groupId":"OG001","value":"84"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"33.3"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"66.7"}]}]},{"title":"Treatment - Week 12","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"75"},{"groupId":"OG001","value":"78"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"66.7"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"66.7"}]}]},{"title":"Treatment - Week 16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"73"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"33.3"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"66.7"}]}]},{"title":"Treatment - Week 20","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"67"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"66.7"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"66.7"}]}]},{"title":"Treatment - Week 24","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"77"},{"groupId":"OG001","value":"71"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"33.3"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"66.7"}]}]},{"title":"Treatment - Week 28","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"62"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"33.3"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"33.3"}]}]},{"title":"Treatment - Week 32","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"65"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.00","lowerLimit":"0.0","upperLimit":"66.7"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"66.7"}]}]},{"title":"Treatment - Week 36","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"61"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"66.7"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"33.3"}]}]},{"title":"Treatment - Week 40","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"74"},{"groupId":"OG001","value":"50"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"66.7"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"66.7"}]}]},{"title":"Treatment - Week 44","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"62"},{"groupId":"OG001","value":"47"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"100.0"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"66.7"}]}]},{"title":"Treatment - Week 48","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"47"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"66.7"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"33.3"}]}]},{"title":"Treatment - Week 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"44"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"66.7"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"33.3"}]}]},{"title":"Treatment - Week 56","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"61"},{"groupId":"OG001","value":"48"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"33.3"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"33.3"}]}]},{"title":"Treatment - Week 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"47"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"33.3"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"66.7"}]}]},{"title":"Treatment - Week 64","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"55"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"66.7"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"66.7"}]}]},{"title":"Treatment - Week 68","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"34"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"66.7"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"66.7"}]}]},{"title":"Treatment - Week 72","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"34"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"33.3"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"33.3"}]}]},{"title":"Treatment - Week 76","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"66.7"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"33.3"}]}]},{"title":"Treatment - Week 80","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"23"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"33.3"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"33.3"}]}]},{"title":"Treatment - Week 84","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"19"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"33.3"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"33.3"}]}]},{"title":"Treatment - Week 88","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"16"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"66.7"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"66.7"}]}]},{"title":"Treatment - Week 92","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"33.3"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"33.3"}]}]},{"title":"Treatment - Week 96","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"66.7"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"33.3"}]}]},{"title":"Treatment - Week 100","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"66.7"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"33.3"}]}]},{"title":"Treatment - Week 104","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"33.33","lowerLimit":"0.0","upperLimit":"66.7"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"33.3"}]}]},{"title":"Treatment - Week 108","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"66.7"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"33.3"}]}]},{"title":"Treatment - Week 112","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"66.7"},{"groupId":"OG001","value":"16.67","lowerLimit":"0.0","upperLimit":"33.3"}]}]},{"title":"Treatment - Week 116","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"33.3"},{"groupId":"OG001","value":"16.67","lowerLimit":"0.0","upperLimit":"33.3"}]}]},{"title":"Treatment - Week 120","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"66.7"}]}]}]},{"type":"SECONDARY","title":"HRQoL by EORTC Quality of Life Questionnaire LC13 Score Pain in Arm and Shoulder","description":"The EORTC QLQ-LC13 module generated one multiple-item scale score assessing dyspnea and a series of single item scores assessing chest pain, arm/shoulder pain, pain in other parts, coughing, sore mouth, dysphagia, peripheral neuropathy, alopecia, and hemoptysis. All the scales and single-item scores were linearly transformed so that each score ranged from 0 to 100. A higher score on the global health and functioning subscales is indicative of better functioning.","populationDescription":"ITT population included all participants randomized in the study, irrespective of whether or not they received study drug. Number analyzed indicates number of participants evaluated for specified time points.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"Score on a scale","timeFrame":"Baseline, every 4 weeks until disease progression (up to 33 months)","groups":[{"id":"OG000","title":"Alectinib","description":"Participants received alectinib at 600 mg orally BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death."},{"id":"OG001","title":"Crizotinib","description":"Participants received crizotinib at 250 mg orally BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"152"},{"groupId":"OG001","value":"151"}]}],"classes":[{"title":"Baseline","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"100"},{"groupId":"OG001","value":"96"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"100.0"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"100.0"}]}]},{"title":"Treatment - Week 4","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"95"},{"groupId":"OG001","value":"89"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"66.7"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"100.0"}]}]},{"title":"Treatment - Week 8","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"89"},{"groupId":"OG001","value":"84"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"100.0"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"66.7"}]}]},{"title":"Treatment - Week 12","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"75"},{"groupId":"OG001","value":"78"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"100.0"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"66.7"}]}]},{"title":"Treatment - Week 16","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"79"},{"groupId":"OG001","value":"73"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"66.7"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"66.7"}]}]},{"title":"Treatment - Week 20","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"67"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"66.7"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"66.7"}]}]},{"title":"Treatment - Week 24","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"77"},{"groupId":"OG001","value":"71"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"33.3"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"66.7"}]}]},{"title":"Treatment - Week 28","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"62"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"66.7"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"66.7"}]}]},{"title":"Treatment - Week 32","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"65"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"66.7"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"100.0"}]}]},{"title":"Treatment - Week 36","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"61"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"100.0"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"66.7"}]}]},{"title":"Treatment - Week 40","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"74"},{"groupId":"OG001","value":"50"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"66.7"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"100.0"}]}]},{"title":"Treatment - Week 44","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"62"},{"groupId":"OG001","value":"47"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"66.7"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"100.0"}]}]},{"title":"Treatment - Week 48","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"67"},{"groupId":"OG001","value":"47"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"66.7"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"66.7"}]}]},{"title":"Treatment - Week 52","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"44"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"66.7"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"66.7"}]}]},{"title":"Treatment - Week 56","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"61"},{"groupId":"OG001","value":"48"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"66.7"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"66.7"}]}]},{"title":"Treatment - Week 60","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"47"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"66.7"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"66.7"}]}]},{"title":"Treatment - Week 64","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"55"},{"groupId":"OG001","value":"39"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"66.7"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"66.7"}]}]},{"title":"Treatment - Week 68","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"34"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"66.7"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"66.7"}]}]},{"title":"Treatment - Week 72","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"34"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"66.7"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"66.7"}]}]},{"title":"Treatment - Week 76","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"66.7"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"33.3"}]}]},{"title":"Treatment - Week 80","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"23"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"66.7"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"33.3"}]}]},{"title":"Treatment - Week 84","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"19"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"66.7"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"33.3"}]}]},{"title":"Treatment - Week 88","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"16"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"66.7"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"66.7"}]}]},{"title":"Treatment - Week 92","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"13"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"66.7"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"100.0"}]}]},{"title":"Treatment - Week 96","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"11"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"33.33","lowerLimit":"0.0","upperLimit":"66.7"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"33.3"}]}]},{"title":"Treatment - Week 100","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"10"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"33.33","lowerLimit":"0.0","upperLimit":"66.7"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"66.7"}]}]},{"title":"Treatment - Week 104","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"33.33","lowerLimit":"0.0","upperLimit":"66.7"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"33.3"}]}]},{"title":"Treatment - Week 108","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"7"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"66.7"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"33.3"}]}]},{"title":"Treatment - Week 112","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"4"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","lowerLimit":"0.0","upperLimit":"66.7"},{"groupId":"OG001","value":"16.67","lowerLimit":"0.0","upperLimit":"33.33"}]}]},{"title":"Treatment - Week 116","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"2"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"16.67","lowerLimit":"0.0","upperLimit":"33.33"},{"groupId":"OG001","value":"16.67","lowerLimit":"0.0","upperLimit":"33.33"}]}]},{"title":"Treatment - Week 120","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"33.33","lowerLimit":"33.33","upperLimit":"33.33"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Baseline up to 43 months","eventGroups":[{"id":"EG000","title":"Alectinib","description":"Participants received alectinib at 600 mg orally BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death.","deathsNumAffected":35,"deathsNumAtRisk":152,"seriousNumAffected":44,"seriousNumAtRisk":152,"otherNumAffected":136,"otherNumAtRisk":152},{"id":"EG001","title":"Crizotinib","description":"Participants received crizotinib at 250 mg orally BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death.","deathsNumAffected":40,"deathsNumAtRisk":151,"seriousNumAffected":45,"seriousNumAtRisk":151,"otherNumAffected":140,"otherNumAtRisk":151}],"seriousEvents":[{"term":"Pneumonitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":152},{"groupId":"EG001","numAffected":4,"numAtRisk":151}]},{"term":"Pneumothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":152},{"groupId":"EG001","numAffected":0,"numAtRisk":151}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":152},{"groupId":"EG001","numAffected":1,"numAtRisk":151}]},{"term":"Pulmonary Embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":152},{"groupId":"EG001","numAffected":3,"numAtRisk":151}]},{"term":"Bronchopleural Fistula","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":152},{"groupId":"EG001","numAffected":0,"numAtRisk":151}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":152},{"groupId":"EG001","numAffected":1,"numAtRisk":151}]},{"term":"Pleural Effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":152},{"groupId":"EG001","numAffected":1,"numAtRisk":151}]},{"term":"Pulmonary Haemorrhage","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":152},{"groupId":"EG001","numAffected":0,"numAtRisk":151}]},{"term":"Respiratory Failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":152},{"groupId":"EG001","numAffected":1,"numAtRisk":151}]},{"term":"Interstitial Lung Disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":152},{"groupId":"EG001","numAffected":1,"numAtRisk":151}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":152},{"groupId":"EG001","numAffected":4,"numAtRisk":151}]},{"term":"Lung Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":152},{"groupId":"EG001","numAffected":0,"numAtRisk":151}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":152},{"groupId":"EG001","numAffected":0,"numAtRisk":151}]},{"term":"Urinary Tract Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":152},{"groupId":"EG001","numAffected":0,"numAtRisk":151}]},{"term":"Bacteraemia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":152},{"groupId":"EG001","numAffected":0,"numAtRisk":151}]},{"term":"Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":152},{"groupId":"EG001","numAffected":0,"numAtRisk":151}]},{"term":"Herpes Zoster","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":152},{"groupId":"EG001","numAffected":0,"numAtRisk":151}]},{"term":"Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":152},{"groupId":"EG001","numAffected":0,"numAtRisk":151}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":152},{"groupId":"EG001","numAffected":0,"numAtRisk":151}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":152},{"groupId":"EG001","numAffected":1,"numAtRisk":151}]},{"term":"Skin Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":152},{"groupId":"EG001","numAffected":0,"numAtRisk":151}]},{"term":"Upper Respiratory Tract Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":152},{"groupId":"EG001","numAffected":0,"numAtRisk":151}]},{"term":"Acinetobacter Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":152},{"groupId":"EG001","numAffected":1,"numAtRisk":151}]},{"term":"Appendicitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":152},{"groupId":"EG001","numAffected":1,"numAtRisk":151}]},{"term":"Necrotising Fasciitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":152},{"groupId":"EG001","numAffected":1,"numAtRisk":151}]},{"term":"Oesophageal Candidiasis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":152},{"groupId":"EG001","numAffected":1,"numAtRisk":151}]},{"term":"Pneumonia Klebsiella","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":152},{"groupId":"EG001","numAffected":1,"numAtRisk":151}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":152},{"groupId":"EG001","numAffected":3,"numAtRisk":151}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":152},{"groupId":"EG001","numAffected":1,"numAtRisk":151}]},{"term":"Chest Discomfort","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":152},{"groupId":"EG001","numAffected":1,"numAtRisk":151}]},{"term":"Hyperthermia Malignant","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":152},{"groupId":"EG001","numAffected":1,"numAtRisk":151}]},{"term":"Multiple Organ Dysfunction Syndrome","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":152},{"groupId":"EG001","numAffected":1,"numAtRisk":151}]},{"term":"Sudden Death","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":152},{"groupId":"EG001","numAffected":1,"numAtRisk":151}]},{"term":"Chest Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":152},{"groupId":"EG001","numAffected":0,"numAtRisk":151}]},{"term":"Death","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":152},{"groupId":"EG001","numAffected":0,"numAtRisk":151}]},{"term":"Oedema","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":152},{"groupId":"EG001","numAffected":0,"numAtRisk":151}]},{"term":"Aphasia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":152},{"groupId":"EG001","numAffected":1,"numAtRisk":151}]},{"term":"Cerebral Haemorrhage","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":152},{"groupId":"EG001","numAffected":1,"numAtRisk":151}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":152},{"groupId":"EG001","numAffected":1,"numAtRisk":151}]},{"term":"Epilepsy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":152},{"groupId":"EG001","numAffected":1,"numAtRisk":151}]},{"term":"Hemiparesis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":152},{"groupId":"EG001","numAffected":1,"numAtRisk":151}]},{"term":"Seizure","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":152},{"groupId":"EG001","numAffected":1,"numAtRisk":151}]},{"term":"Haemorrhage Intracranial","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":152},{"groupId":"EG001","numAffected":0,"numAtRisk":151}]},{"term":"Hypoglycaemic Coma","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":152},{"groupId":"EG001","numAffected":0,"numAtRisk":151}]},{"term":"Acute Myocardial Infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":152},{"groupId":"EG001","numAffected":1,"numAtRisk":151}]},{"term":"Atrial Fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":152},{"groupId":"EG001","numAffected":1,"numAtRisk":151}]},{"term":"Cardiac Arrest","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":152},{"groupId":"EG001","numAffected":1,"numAtRisk":151}]},{"term":"Myocardial Infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":152},{"groupId":"EG001","numAffected":1,"numAtRisk":151}]},{"term":"Sinus Bradycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":152},{"groupId":"EG001","numAffected":1,"numAtRisk":151}]},{"term":"Cardiac Tamponade","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":152},{"groupId":"EG001","numAffected":0,"numAtRisk":151}]},{"term":"Pericardial Effusion","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":152},{"groupId":"EG001","numAffected":0,"numAtRisk":151}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":152},{"groupId":"EG001","numAffected":3,"numAtRisk":151}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":152},{"groupId":"EG001","numAffected":2,"numAtRisk":151}]},{"term":"Gastrointestinal Disorder","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":152},{"groupId":"EG001","numAffected":1,"numAtRisk":151}]},{"term":"Ileus","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":152},{"groupId":"EG001","numAffected":1,"numAtRisk":151}]},{"term":"Oesophagitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":152},{"groupId":"EG001","numAffected":1,"numAtRisk":151}]},{"term":"Blood Creatinine Increased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":152},{"groupId":"EG001","numAffected":0,"numAtRisk":151}]},{"term":"Alanine Aminotransferase Increased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":152},{"groupId":"EG001","numAffected":4,"numAtRisk":151}]},{"term":"Aspartate Aminotransferase Increased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":152},{"groupId":"EG001","numAffected":1,"numAtRisk":151}]},{"term":"Human Chorionic Gonadotropin Increased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":152},{"groupId":"EG001","numAffected":0,"numAtRisk":151}]},{"term":"Deep Vein Thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":152},{"groupId":"EG001","numAffected":2,"numAtRisk":151}]},{"term":"Lymphoedema","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":152},{"groupId":"EG001","numAffected":1,"numAtRisk":151}]},{"term":"Orthostatic Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":152},{"groupId":"EG001","numAffected":1,"numAtRisk":151}]},{"term":"Thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":152},{"groupId":"EG001","numAffected":1,"numAtRisk":151}]},{"term":"Cholelithiasis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":152},{"groupId":"EG001","numAffected":1,"numAtRisk":151}]},{"term":"Drug-Induced Liver Injury","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":152},{"groupId":"EG001","numAffected":1,"numAtRisk":151}]},{"term":"Hepatic Haematoma","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":152},{"groupId":"EG001","numAffected":1,"numAtRisk":151}]},{"term":"Hepatic Haemorrhage","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":152},{"groupId":"EG001","numAffected":0,"numAtRisk":151}]},{"term":"Hepatotoxicity","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":152},{"groupId":"EG001","numAffected":0,"numAtRisk":151}]},{"term":"Cholecystitis Acute","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":152},{"groupId":"EG001","numAffected":0,"numAtRisk":151}]},{"term":"Confusional State","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":152},{"groupId":"EG001","numAffected":2,"numAtRisk":151}]},{"term":"Vision Blurred","organSystem":"Eye disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":152},{"groupId":"EG001","numAffected":1,"numAtRisk":151}]},{"term":"Forearm Fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":152},{"groupId":"EG001","numAffected":1,"numAtRisk":151}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":152},{"groupId":"EG001","numAffected":1,"numAtRisk":151}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":152},{"groupId":"EG001","numAffected":1,"numAtRisk":151}]},{"term":"Ovarian Cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":152},{"groupId":"EG001","numAffected":1,"numAtRisk":151}]},{"term":"Renal Impairment","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":152},{"groupId":"EG001","numAffected":1,"numAtRisk":151}]},{"term":"Acute Kidney Injury","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":152},{"groupId":"EG001","numAffected":0,"numAtRisk":151}]},{"term":"Urinary Retention","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":152},{"groupId":"EG001","numAffected":0,"numAtRisk":151}]},{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":152},{"groupId":"EG001","numAffected":0,"numAtRisk":151}]},{"term":"Thoracic Vertebral Fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":152},{"groupId":"EG001","numAffected":0,"numAtRisk":151}]},{"term":"Back Pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":152},{"groupId":"EG001","numAffected":0,"numAtRisk":151}]},{"term":"Disorientation","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":152},{"groupId":"EG001","numAffected":0,"numAtRisk":151}]},{"term":"Uterine Polyp","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":152},{"groupId":"EG001","numAffected":0,"numAtRisk":151}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":152},{"groupId":"EG001","numAffected":0,"numAtRisk":151}]},{"term":"Oedema Peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":152},{"groupId":"EG001","numAffected":1,"numAtRisk":151}]}],"otherEvents":[{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":52,"numAtRisk":152},{"groupId":"EG001","numAffected":49,"numAtRisk":151}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":21,"numAtRisk":152},{"groupId":"EG001","numAffected":70,"numAtRisk":151}]},{"term":"Diarrohea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":18,"numAtRisk":152},{"groupId":"EG001","numAffected":68,"numAtRisk":151}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":152},{"groupId":"EG001","numAffected":57,"numAtRisk":151}]},{"term":"Abdominal Pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":152},{"groupId":"EG001","numAffected":7,"numAtRisk":151}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":152},{"groupId":"EG001","numAffected":12,"numAtRisk":151}]},{"term":"Abdominal Pain Upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":152},{"groupId":"EG001","numAffected":6,"numAtRisk":151}]},{"term":"Dysphagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":152},{"groupId":"EG001","numAffected":8,"numAtRisk":151}]},{"term":"Oedema Peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":26,"numAtRisk":152},{"groupId":"EG001","numAffected":41,"numAtRisk":151}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":29,"numAtRisk":152},{"groupId":"EG001","numAffected":25,"numAtRisk":151}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":152},{"groupId":"EG001","numAffected":11,"numAtRisk":151}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":152},{"groupId":"EG001","numAffected":9,"numAtRisk":151}]},{"term":"Chest Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":152},{"groupId":"EG001","numAffected":5,"numAtRisk":151}]},{"term":"Alanine Aminotransferase Increased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":22,"numAtRisk":152},{"groupId":"EG001","numAffected":42,"numAtRisk":151}]},{"term":"Aspartate Aminotransferase Increased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":20,"numAtRisk":152},{"groupId":"EG001","numAffected":37,"numAtRisk":151}]},{"term":"Blood Bilirubin Increased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":23,"numAtRisk":152},{"groupId":"EG001","numAffected":2,"numAtRisk":151}]},{"term":"Blood Creatinine Increased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":152},{"groupId":"EG001","numAffected":6,"numAtRisk":151}]},{"term":"Blood Creatine Phosphokinase Increased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":152},{"groupId":"EG001","numAffected":7,"numAtRisk":151}]},{"term":"Weight Increased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":15,"numAtRisk":152},{"groupId":"EG001","numAffected":0,"numAtRisk":151}]},{"term":"Blood Alkaline Phosphatase Increased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":152},{"groupId":"EG001","numAffected":8,"numAtRisk":151}]},{"term":"Gamma-Glutamyltransferase Increased","organSystem":"Investigations","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":152},{"groupId":"EG001","numAffected":10,"numAtRisk":151}]},{"term":"Dysgeusia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":152},{"groupId":"EG001","numAffected":29,"numAtRisk":151}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":152},{"groupId":"EG001","numAffected":20,"numAtRisk":151}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":152},{"groupId":"EG001","numAffected":13,"numAtRisk":151}]},{"term":"Paraesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":152},{"groupId":"EG001","numAffected":8,"numAtRisk":151}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":17,"numAtRisk":152},{"groupId":"EG001","numAffected":10,"numAtRisk":151}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":24,"numAtRisk":152},{"groupId":"EG001","numAffected":3,"numAtRisk":151}]},{"term":"Back Pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":152},{"groupId":"EG001","numAffected":7,"numAtRisk":151}]},{"term":"Pain In Extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":152},{"groupId":"EG001","numAffected":10,"numAtRisk":151}]},{"term":"Musculoskeletal Pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":152},{"groupId":"EG001","numAffected":3,"numAtRisk":151}]},{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":29,"numAtRisk":152},{"groupId":"EG001","numAffected":7,"numAtRisk":151}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":152},{"groupId":"EG001","numAffected":11,"numAtRisk":151}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":16,"numAtRisk":152},{"groupId":"EG001","numAffected":14,"numAtRisk":151}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":152},{"groupId":"EG001","numAffected":11,"numAtRisk":151}]},{"term":"Photosensitivity Reaction","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":152},{"groupId":"EG001","numAffected":0,"numAtRisk":151}]},{"term":"Visual Impairment","organSystem":"Eye disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":152},{"groupId":"EG001","numAffected":18,"numAtRisk":151}]},{"term":"Vision Blurred","organSystem":"Eye disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":152},{"groupId":"EG001","numAffected":10,"numAtRisk":151}]},{"term":"Photopsia","organSystem":"Eye disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":152},{"groupId":"EG001","numAffected":9,"numAtRisk":151}]},{"term":"Upper Respiratory Tract Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":13,"numAtRisk":152},{"groupId":"EG001","numAffected":13,"numAtRisk":151}]},{"term":"Urinary Tract Infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":152},{"groupId":"EG001","numAffected":7,"numAtRisk":151}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":152},{"groupId":"EG001","numAffected":9,"numAtRisk":151}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":152},{"groupId":"EG001","numAffected":6,"numAtRisk":151}]},{"term":"Productive Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":152},{"groupId":"EG001","numAffected":1,"numAtRisk":151}]},{"term":"Bradycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":152},{"groupId":"EG001","numAffected":14,"numAtRisk":151}]},{"term":"Sinus Bradycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":152},{"groupId":"EG001","numAffected":7,"numAtRisk":151}]},{"term":"Decreased Appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":14,"numAtRisk":152},{"groupId":"EG001","numAffected":14,"numAtRisk":151}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA Version 19.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":15,"numAtRisk":152},{"groupId":"EG001","numAffected":9,"numAtRisk":151}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights."},"pointOfContact":{"title":"Medical Communications","organization":"Hoffmann-La Roche","email":"genentech@druginfo.com","phone":"800-821-8590"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2018-02-06","uploadDate":"2018-02-06T10:36","filename":"Prot_001.pdf","size":9124884},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2018-02-06","uploadDate":"2018-02-06T10:36","filename":"SAP_000.pdf","size":598006}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17","removedCountries":["Denmark","Dominican Republic","Germany","Greece","Peru","Sweden"]},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C582670","term":"alectinib"},{"id":"D000077547","term":"Crizotinib"}],"ancestors":[{"id":"D010880","term":"Piperidines"},{"id":"D006573","term":"Heterocyclic Compounds, 1-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"},{"id":"D000631","term":"Aminopyridines"},{"id":"D011725","term":"Pyridines"}]}},"hasResults":true}